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High-Resolution Saturation Transfer Difference (STD) 1H NMR 
techniques and Docking simulations applied to Protein-ligand 
interactions 
 
Abstract The study of ligand–receptor interactions using high-resolution NMR 
techniques, namely the saturation transfer difference (STD), is presented for the 
recognition process between different complexes. From diagnostic to therapeutic 
complexes, these approaches were used for direct determination of positive binding, 
followed by the estimation of the correspondent dissociation constant (KD), GEM 
characterization and site preference by competitive experiments. To get a three-
dimensional view of the interaction similar docking simulations were performed for all 
the ligands.  
The enantioselective binding of the (SSS)-! isomer of an yttrium (III) 
tetraazatriphenylene complex to ‘drug-site II’ of human serum albumin (HSA) was 
detected by the intensity differences of its STD 1H NMR spectrum relative to the 
(RRR)-" isomer, by the effect of the competitive binder to that site, N-dansyl 
sarcosine. 
Three MRI contrast agents and the KD for this interaction with HSA was found for all 
complexes using the initial slopes protocol. La(BOPTA) and La(DTPA-Cholate) 
interact mainly with HSA´s drug site I while La(NAPHTO) does not posses a 
specificity for both drug sites. La(DTPA-Cholate) CA analogue was found to have a 
lower KD due to the full lodging of its Cholate moiety in HSA drug site I.  
Insulin mimetic VO(DMPP) complexes preferred binding to ‘drug-site I’ of HSA was 
also detected by STD 1H NMR by the displacement effect of the competitive binder to 
that site, warfarin.  
The protocol of STD and competitive STD followed by docking simulations was found 
to be a robust tool to characterize protein-ligand interactions. 
 
Keywords: protein-ligand interaction – STD NMR – docking simulations – 
competitive STD  
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Transferência de Saturação por Diferença (TSD) usando RMN 
de 1H de alta resolução e simulações de Docking aplicadas a 
interações Ligando-Proteína  
 
Resumo O estudo das interações ligando-receptor através de RMN de alta 
resolução tornou-se muito mais acessível e com um conjunto de aplicações mais 
vasto com o desenvolvimento da técnica de Transferência de Saturação por 
Diferença (TSD). O processo de transporte e reconhecimento de possiveis agentes 
de diagnóstico e terapia foram caracterizados pela sua constante de dissociação 
(KD), pelo seu mapeamento de epitopo e a preferência pelo local de ligação à 
Albumina do Soro Humano (ASH) realizado por TSD competitiva. Um modelo tri-
dimensional foi estabelicido para todas as interacções de modo a complementar a 
informação recolhida por RMN. 
A ligação enantioseletiva de dois complexos de Yttrium revelou a preferência  do 
isómero (SSS)-! relativamente ao isómero (RRR)-". Usando um competidor 
especifico para o local II da ASH e recorrendo a TSD competitivo foi estabelecido 
como lugar de ligação o este mesmo local, reforçando a sua seletividade.  
Três agentes de contraste para Ressonância Magnética foram caracterizados 
usando o protocolo de TSD e o método dos parciais iniciais foi aplicado para a 
obtenção de constantes de dissociação (KD). O La(BOPTA) e o La(DTPA-Colato) 
foram selectivos para o local I, enquanto que o La(NAFTO-EGTA) não parece 
apresentar especificidade para nenhum dos locais de ligação estudados. O 
La(DTPA-Colato) devido a conseguir interagir pela porção do Colato com a ASH 
apresenta uma maior afinidade para o local que o La(BOPTA). 
O insulino-mimético HDMPP foi também estudado e assume-se que este possa ser 
transportado ligado ao local I da ASH, e que todas as suas espécies em solução são 
capazes de interagir com a ASH. 
Este protocolo desenvolvido baseia-se na aquisição de espetros de TSD usando 
RMN, com e sem competição especifica para o local, finalizado por  simulações de 
docking apresenta-se aqui como uma ferramenta bastante útil para estudar 
interações de pequenos ligandos e proteínas. 
 
Palavras chave: interação ligando-proteína – TSD usando RMN – 
simulações de docking– TSD competitivo 
  
 
 
 
 
 
 
1. INTRODUCTION 
 
 
!!
!
"!
INTRODUCTION 
 
Over the past 25 years, advances in structural biology have profoundly 
changed the way in which drugs are designed and discovered. Today, rather 
than treating protein targets as simple black boxes, pharmaceutical scientists are 
now treating them as complex molecular entities that possess well-defined 
structures with active sites that can be rationally activated or deactivated with 
small molecule ligands. Innovations in structure determination methods along 
with rapid advances in molecular visualization tools have led to the emergence of 
structure-aided drug design or rational drug design as an integral part of the drug 
discovery and development process.![1-4] 
Protein interactions with ligands, other proteins, or surfaces are controlled 
by a complex array of intermolecular processes. Such interactions depend both 
on the specificity in the binding site as well as the non-specific forces outside the 
binding pocket. This interplay of specific and non-specific forces controls all 
protein interactions ranging from bimolecular collisions in solutions to adhesion 
between cells. The complexity of interactions between proteins and flexible target 
molecules, including other proteins, nucleic acids and small molecules, is often 
determined by the considerable flexibility of the protein binding sites and by the 
structural rearrangements that occur upon binding of the associated molecule or 
ligands. [5,6] 
A goal of many biophysical studies is to determine the molecular forces 
that control biological interactions and to use this information to rationally 
manipulate protein structure or function by modifying the protein, the interacting 
ligand, or both.  
The forces that control protein behavior and their physical biochemical 
origins are inferred from thermodynamic parameters and equilibrium binding 
kinetic measurements. Calculated energies are used to identify the role of the 
physical and chemical interactions in protein function and behavior. Although 
detailed calculations are feasible for small molecules, such calculations become 
limited as the size and complexity of the biological macromolecules increase. 
Time-dependent forces between soft or mobile species add yet another degree of 
complexity, while static models of interactions cannot describe the full range of 
parameters that influence biological behavior. [5-7] 
1.  
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An accurate understanding, at the molecular level of several biological and 
biochemical processes is indispensable to deal with the specific mechanisms of 
life itself. Many techniques may enhance this desirable goal, such as x-ray 
analysis, in vivo experiments and NMR-based methods, among others. [2, 8-11] 
NMR methods used in this context can be divided into two categories; 
protein based, and ligand based experiments. Recently, there has been a strong 
emphasis on so-called ligand-based because these methods are capable of 
yielding good results versus time ratio, and outputs more advantages than the 
protein based protocols, that may require isotopically labeled protein samples. 
[12-14] 
 Ligand-based methods are attractive because they are broadly applicable, 
impose few constraints on the composition of the target protein and don't require 
isotopic labeling of the protein or ligands. Such experiments include diffusion 
experiments, saturation transfer difference (STD-NMR), NOE pumping, 
waterLOGSY (water Ligand-Observed via Gradient SpectroscopY), SALMON 
(Solvent Accessibility, Ligand binding, and Mapping of ligand Orientation by NMR 
spectroscopy), transferred-NOE (tr-NOE) and INPHARMA. Ligand-based NMR 
methods have been employed in screening and in lead optimization to a broad 
spectrum of biological contexts. One key advantage arises from their capability to 
pick up specific interactions for compounds of relatively low affinity and their 
ability to provide limited structural information without any need of crystallization 
or isotopic labeling. [15,16] 
The saturation transfer difference (STD) is one of these techniques that 
screen ligands for binding activity to proteins. The adoption of this model inherits 
excellent advantages since the total amount of protein needed is very low, in the 
!M range, it is relatively easy to implement, and also can be associated with 
other NMR sequences, and can be applied to large molecular weight diagnostic 
and therapeutic targets. The type of data possible to obtain from this technique 
includes dissociation constant estimation and group epitope mapping (GEM). 
Being a very versatile experiment it can be used almost in all problems that need 
this kind of data unveiled. [17-20] 
One of these fields is Magnetic Resonance Imaging (MRI), where these 
approaches might resolve most of the challenges on improving the contrast 
agent-protein interactions. [21,22] 
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MRI is a non-invasive diagnostic technique used to provide anatomical 
and functional images of the human body which can use paramagnetic 
complexes able to enhance the image contrast by increasing the nuclear 
relaxation rates of water protons in the surrounding tissues, differing to other 
contrast agents (CA’s) used in other clinical imaging studies which are directly 
imaged. Gadolinium (III) polyaminocarboxyl chelates have been under 
development for their late use, prior to scan, of administrable contrast agents. 
The use of this ion with seven unpaired electrons, nine coordination sites and 
favorable electronic relaxation times bound to a ligand non-covalent binding to 
Human Serum Albumin (HSA) became an issue of great relevance when 
studying new possible contrast agents for Magnetic Resonance Angiography 
(MRA) once the lifetime of CA in blood increases when this interaction occurs. 
[21-23] Given this feature, and being Albumin the most abundant soluble protein 
in the body of all vertebrates and the most prominent protein in plasma, its ligand 
and protein binding study has become a powerful tool for the process. [21] 
Most of the compounds interacting with HSA are hydrophobic organic 
anions and the search for new CAs for angiographic applications has been 
addressed to Gd (III) complexes endowed with lipophilic substituents and 
residual negative charge. [23] 
The full scope of this interaction is completed with virtual ligand screening 
using in silico methods. The growing importance of structure-based drug design 
is due to a wide range of relatively fast answers, as it can provide prospective 
leads and also is a practical alternative or complement to high-throughput 
screening of large compound libraries and, even, affinities of the distinct ligands 
can be predicted correctly. The docking and scoring problems countered in this 
endeavor are central to the theory of biomolecular interactions and are ultimately 
determined by the nature of the underlying binding energy landscape. However, 
once the desired synergy of adequate conformational sampling combined with 
accurate evaluation of energetics has been difficult to achieve with any 
computational models a constant effort is being carried out. [24,25,26] 
Docking software, like Autodock Vina, may build a valid 3D model of the 
interaction used to confirm or discard previous collected data. The premise that a 
biological function can be described by a similarity in binding sites and ligand 
interactions with proteins of known function is the basis for the outlined protocol 
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in this year of work. The resulting co-structure and functional assignment may 
provide a starting point for a drug discovery effort. [25] 
Complete information about the ligand binding to a specific protein region 
with a quantitative analysis (that may be obtained by STD-NMR) and a 3D model 
(obtained by docking simulations) fully characterizes the ligand-binding 
phenomena. Not only a given relationship is unveiled but also similar binding 
modes may reduce the drug discover effort and timeline.  
The studied HSA binding diamagnetic analogues of contrast agents were: 
La(BOPTA), La(DTPA-Cholate), La(NAFTO-EGTA) (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 Figure 1. Chemical structures of the studied ligands and 3D view for the La(III) complexes: 
 1 – BOPTA, 2 – DTPA-Cholate and 3 – NAPHTO-EGTA. 
!!
!
"!
The study of a case of enantiselective binding to HSA was performed with 
two complexes the RRR-(!)-[Y.L1]3+ and SSS-(")-[Y.L1]3+  (Fig. 2) to verify if 
STD-NMR can distinguish between them and if so where does this type of 
complex binds using also a competitive assay with N-dansyl sarcosine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A promising possible insulin mimetic V(IV) complex binding to HSA is also 
going to be studied to see how it is transported in the blood stream in a HSA-
binding model. 
 
Figure 2. Chemical structures of the studied complexes. 1 – SSS-(")-[Y.L1]3+and 2 – RRR-(!)-
[Y.L1]3+. 
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The study of all the interaction between the compounds and HSA and 
where the binding occurs will be performed with the STD-NMR protocol and with 
the competitive assays using known binders to the HSA binding sites reported by 
Sudlow [27] (Scheme 1), and later verified using Autodock Vina and Poseview 
software [28,29] for 3D and 2D models of the interaction, respectively. 
In the present work a complete explanation of the STD technique is going 
to be documented with all the known possible approaches and the interpretation 
of the given sequence. A few brief technical considerations, according to the 
spectrometer and software used, are posted in Materials and Methods section.  
 
 
 
 
 
Scheme 1. Scheme for all binders used for competition. 1- Warfarin, 2- Ibuprofen, 3- L-Tryptophan and 4- N-dansyl 
sarcosine. 
 
  
Figure 3. Chemical structures for the insulin mimetic and all solution species. 1 – HDMPP, 2 –
1:1 VO2(DMPP)(H2O)(OH) and 3 - 1:2 VO2(DMPP)2. 
!!
!
"!
 
 
 
 
 
 
 
 
2. OBJECTIVES 
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2. Objectives  
 
The first objective of this work is to study if STD-NMR can distinguish 
between the enantiomeric complexes SSS-(!)-[Y.L1]3+ and RRR-(")-[Y.L2]3+ in 
their binding to HSA. Knowing that recent crystallographic studies of HSA 
complexes have suggested that “drug site II” is the most stereo-differentiating 
protein binding site, in human serum albumin, we use a known binder for that 
site,  N-dansyl sarcosine, to perform competitive STD experiments. 
The second objective of this work was to determine the interaction of 
selective contrast agents with HSA, providing enough data to study the binding 
behavior of the ligands, the establishment of the binding epitopes, to disclose the 
favorable binding site, and to estimate their affinity constants using the binding 
isotherm of STD initial growth rates method. The CA analogues can be 
summarized as being: La(BOPTA), La(DTPA-Cholate) and La(NAPHTO-EGTA). 
To achieve the objective of binding site definition, four known inhibitors were 
used to, primarily, clarify the binding site of the selected compound. (Warfarin, 
Ibuprofen and L-Tryptophan) 
The third objective was to characterize the interaction of insulin mimetic 
VO(DMPP)2 complex with is main carrier in the blood stream, HSA.  
The fourth, and overall, objective was, after the NMR conclusions, the 
obtention of a three-dimensional model for the interaction. Since the protein used 
presents a huge variety of structures already available to any user, suitable 
models were easy to select. 
With the fulfillment of the proposed objectives we intend to implement a 
valid, and relatively fast, protocol for detecting protein-ligand interactions. Using 
diagnostic and therapy agents, the objectives represent an ambitious and 
complete characterization method.  
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3. THEORETICAL BACKGROUND 
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3. THEORETICAL BACKGROUND 
 The characterization of events between a ligand and its receptor is a 
powerful tool to the development of new drug-based researches and the 
possibility of knowing binding strength, kinetics, competitive binding, as well as 
allosteric effects made this long way a lot shorter. 
Nowadays the conventional bioassay-based high-throughput screening 
(HTS) is very popular for the development of alternative and complementary 
tools. The NMR-based methods have been appearing, in this last years, as very 
robust to emulate the outputs in new drug discovery, on a broad spectrum of 
biological processes like antibodies, peptide inhibitors, enzyme substrates, RNA 
and DNA-protein interactions among many others. [30-32] 
When studying the interaction between a ligand and its receptor, or 
between proteins, many difficulties may arise at any moment, such the large 
amount of possible ligand candidates differing from each other, and how to 
gather all the information needed to choose the ones that really matter.  
This section has the purpose of briefly reporting the main NMR-based 
techniques used to study ligand-receptor interactions namely, Water-Ligand 
Observed via Gradient Spectroscopy (WaterLOGSY), Tranferred NOE’s, Structur 
Activity Relationship (SAR) by NMR and Saturation Transfer Difference (STD) – 
NMR and how they may overcome some difficulties of detection and 
characterization of ligand binding processes. [33] 
 
3.1.  WATERLOGSY 
 
Popular among NMR-based screening techniques, the WaterLOGSY 
experiment was first reported by Dalvit et. al [34,35] and its name is derived from 
Water Ligand Observed via Gradient Spectroscopy.  
The WaterLOGSY experiment allows the discrimination between binding 
and nonbinding ligands in a mixture and consists in the labeling of the bound 
ligand with a saturation profile. The saturation label is transferred to the binding 
components of the mixture via bulk water.  
Initially, two ways to affect the water magnetization were proposed: a 
selective saturation and a selective inversion of the solvent magnetization, which 
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can be achieved by two distinct methods, either by the WEXII proposed by Mori 
et al. or by the ePHOGSY spin echo scheme proposed by Dalvit. As confirmed 
by recent literature the ePHOGSY methods become more efficient. [34,38] 
In order to apprehend how WaterLOGSY (ePHOGSY) works, the NMR 
sequence of the method (Fig. 4) has a first section representing the ePHOGSY 
spin echo, responsible for the inversion of the water magnetization. The narrow 
and broad rectangular shapes correspond to 90º and 180º hard pulses, 
respectively. The first 90º pulse sets every magnetization on the transversal 
plane. The first gradient G1 defocuses the entire magnetization. Then the 
selective 180º pulse (!1) affecting only the water signal, enables water 
refocusing; the second G1 gradient enhances the defocusing of the off 
resonance signals and refocus the water resonance. The following 90º pulse 
leads to complete inversion of the water magnetization. The selective 180º pulse 
shifts its phase by 90º each scan by phase cycling. 
Because of the selective irradiation of the water signal, those resonances 
that lay close to it may also be affected if the pulse is not fully calibrated and set. 
Now, the inverted magnetization needs to be transferred to the bound 
ligands. To accomplish that, an evolution time, typically 1 to 3 seconds, needed 
for the NOEs to take effect, is required. For the mixing time ("m) a sustained 
weak gradient G4 gradient is applied to avoid fast relaxation due to radiation 
dumping. The strong crushing additional G5 is optional and its application 
accounts for the same purpose as G4. [31,38]  
 
 
 
 
 
 
 
 
Figure 4. Pulse sequence for the homonuclear one-dimensional ePHOGSY. 
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 There are two possible simultaneous pathways for the inverted 
magnetization of water to be transferred to the bound ligand. Along with the 
ligand in the pocket site of the receptor, there are “bound” water molecules 
whose magnetization is now inverted. The “bound” condition of the water 
molecules relies on the fact that their residence time is longer than the rotational 
correlation time of the large molecular complex, otherwise no inversion would 
occur. The inverted magnetization of these water molecules will pass through 
direct H-H cross-relaxation to the bound ligand. Because these waters are buried 
inside the complex, the cross-relaxation between the bound waters and the 
ligand is negative and tends to bring the ligand magnetization to the inverted 
state. 
The other pathway is through intermolecular exchange of labile carboxyl, 
amino, a hydroxyl, imidazol, guanidinium and amide proton is from either the 
receptor binding pocket or somewhere at its surface. 
Additionally, free ligands (binders and non-binders) also suffer 
magnetization transfer from water, which is also via exchangeable protons and 
posterior spin diffusion. However, in this case, due to the short correlation times 
of free ligands, the cross-relaxation inside the ligands is positive, yielding a NOE 
effect characteristic of fast tumbling small molecules. 
Also a water selective flip-back can be applied before the observe pulse to 
allow fast repetition times and an additional hard 180º pulse can be added in the 
middle of the evolution time for the suppression of artifacts that originate from 
almost complete relaxation of the protons of the small molecules during the long 
mixing period. [39] 
The resulting spectra (Fig. 5) will show binding and non-binding ligand 
signals of opposite phase, due to the different signs of the constants that rule the 
cross-relaxation with short and long correlation time molecules. This allows 
distinguishing between binders and nonbinding ligands where the pool of spin-
inverted binding ligands must overcome the pool of non-inverted-spin ligands on 
the evolution time of the experiment. For that reason, low ligand excess ratios, of 
about 10 or 20 should be enough. 
While the initial waterLOGSY experiment seemed to be limited to the 
identification of binders vs non-binders, recent work showed that waterLOGSY 
can be used to probe for bulk water accessibility to derive the orientation of a 
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bound ligand. This approach has been termed SALMON (Solvent Accessibility 
and protein Ligand binding studied by NMR Spectroscopy) and may be found 
elsewhere. [34,38]  
 
 
 
 
 
 
 
 
 
 
Figure 5. 1H Water-LOGSY spectrum of a library of ten compounds in the presence of a receptor. 
Signals from the indole derivative with binding affinity for the receptor are easily identified 
(positive signals). The upper spectrum displays the 1H NMR reference spectrum. The signals 
belonging to the binding ligand are marked by *.  
 
Being the WaterLOGSY experiment water-dependent, it is limited by the 
fact that fully deuterated solutions are not welcome, and by its inability to identify 
strong ligands with slow dissociation rates. However, it represents a interesting 
NMR approach for primary screening of compounds for binding to the target of 
interest in the µM range. [39] 
 
3.2.  TRANSFERRED NOE’S 
 
The transferred NOE (tr-NOE) effect was originally described by Bothner-
By. Peters was the first to propose the tr-NOE use for screening compound 
mixtures. The tr-NOE (Fig.6) is based on the nuclear Overhauser effect between 
adjacent spins in the ligand in presence of chemical exchange between the 
bound and unbound form. [40-42] 
NOE effects (NOEs) are often used in determining 3D structures of 
compounds in solution, where some magnetization from nucleus I is transferred 
to nucleus S in the mixing period by nuclear relaxation via dipole-dipole coupling. 
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The transferred magnetization will precess (at the Larmor frequency) at the 
chemical shift !I during t1 (Fig. 7), but at the chemical shift !S during mixing time. 
There will be therefore a peak in the two dimensional spectrum with coordinates 
(!I,!S), so we may say that these two spins are correlated. Structurally this 
means that I and S are spatially close (r < 5 Å) and the NOE is a relaxation factor 
that builds-up during the mixing-time. [8] 
 
 
 
 
 
Figure 7 Schematic illustration of the NMR pulse sequence for 2D NOESY experiment. 
 
Low molecular weight (MW) compounds (MW < 2000) have short 
rotational correlation times ("c), therefore presenting positive NOEs. Also, 
depending on compound shape and field strength, low MW molecules can exhibit 
Figure 6. Schematic illustration of the Tr-NOE. Magnetization   is   transferred from ligand A via 
the protein back to itself. 
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no or small negative NOEs. On the other end, large MW molecules, usually 
proteins, due to their long !c’s, show large negative NOEs. Small ligand binding 
to large molecules leads to a drastic change in ligand NOE’s, since the ligand 
starts tumbling at the large receptor tumbling rate. Within a mixture, those ligands 
that bind the receptor show NOEs of opposite sign to the cross-binders as they 
adopt the tumbling behavior of the large receptor – Figure 8. 
 
 
 
 
 
 
 
Figure 8. Schematic illustration of transferred NOE’s experiment. 
 
Additionally, the absolute magnitude of the NOEs is greater in slow 
correlation time molecules and its maximum value, which occurs only if dipole-
dipole relaxation is featured, is more rapidly achieved. [18] 
In tr-NOEs based screens, intramolecular NOEs of compound mixtures 
are observed via 2D-NOESY NMR spectra in the absence and presence of the 
receptor. Binding compounds are identified by NOE crosspeaks that have 
changed sign in the presence of the receptor. It is estimated that tr-NOE is able 
to probe binding affinities between 100 nM " KD " 1 mM, once if the residence 
time isn’t long enough no magnetization will happen, and if the binding is too 
strong no build up of tr-NOE’s would be visible in the final spectrum.[43] 
Besides the binding confirmation, tr-NOE can provide information about 
binding pocket environment: once intramolecular tr-NOEs are the key to define 
bound ligand conformations, intermolecular trNOEs occur between a ligand and a 
receptor protein, and therefore, in principle, allow the determination of the 
orientation of bound ligands in protein binding pockets. [19] 
For a better understanding of the tr-NOE experiment, we must define two 
different concepts: the conformation of a bound ligand and its orientation in the 
binding pocket of the receptor. We can define receptor bound ligand 
conformation as the three dimensional architecture that the ligand adopts when 
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bound to its receptor, normally a protein. The orientation concept translates the 
significant alterations in the orientation of the ligand in the binding pocket that 
may arise from slight structural modifications. 
The receptor-bound conformation of the ligand can be determined either 
by standard NMR techniques using labeled complexes, where the three 
dimensional structure of the complex is depicted, or by transferred NOE or 
transferred cross-relaxation. 
 
3.3.   SAR BY NMR 
 
The advent of the SAR by NMR method is given to S. Fesik at Abbott 
Laboratories. SAR by NMR detects changes in the chemical shifts of the protein 
target upon addition of ligands (Fig. 9). Weakly interacting compounds that bind 
at adjacent sites on the protein target are identified and combined with structural 
information about the orientation of the bound ligands to guide a linked-fragment 
approach to generate lead drug compounds with greatly increased binding. [44]  
Figure 9. SAR by NMR experimental procedure. The 
first step screens ligands using the perturbation 
method with a difference in chemical shift greater 
than 0.1 ppm for at least two peaks in the spectrum. 
After hit identification the binding affinity is measured 
and an optimization is done for this site. The same 
perturbation method is applied to identify a second 
low-affinity hit in the presence of the optimized first 
ligand. Identification and optimization of the second 
binding site follows. 
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The first step of the procedure requires screening a library of ligands using 
the perturbation method with the assumption that a change in chemical shift 
greater than 0.1 ppm for at least two peaks in the spectrum constitutes a 
significant change and indicates binding. After hit identification, monitoring 
chemical shift changes as a function of ligand concentration in a titration 
experiment is performed to accurately deduce the binding constant. Following 
identification of a binding partner to the first site, screening of related compounds 
is conducted to increase and optimize the binding affinity for that site. [45,46] 
The same perturbation method is applied to identify a second low-affinity 
hit in the presence of the optimized first ligand. Following identification and 
optimization of the second binding site, structural data obtained by additional 
experiments is used to determine the location and orientation of the protein target 
in complex with its two low-affinity hits. Maintaining the spatial orientation of the 
compounds with respect to each other and the protein target, the ligands are 
synthetically linked together to produce the high affinity ligand as seen on Figure 
10 illustrative example. [44]  
Binding is detected from the amide chemical shift changes observed in 2D 
Heteronuclear Single Quantum Correlation (HSQC) spectra. The 1H-15N HSQC 
experiment exploits the repeating nature of the protein’s primary sequence and 
three-dimensional structure. The amide bond connects the amino acids that 
compose the protein sequence, creating a repeating series of NH groups that 
become chemically unique in the context of the protein’s tertiary structure. [47] 
 
 
 
 
 
 
 
 
 
 
Figure 10. SAR by NMR example. The identified fragment leads are shown with cyan carbons, 
whereas the linked compounds are denoted with green carbon atoms. Adapted from [44] 
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The experiment only detects those protons directly coupled to nitrogen, so 
the resulting spectrum lacks any overlap from proton signals associated with 
carbon (typically aromatics in the relevant ppm range). The spectrum displays 
one cross peak for amides in the protein at a position characterized by its 1H and 
15N chemical shifts that is an already optimized protocol (Fig. 11). In total, the 
spectrum contains one signal for each residue except proline, which lacks an HN, 
two paired peaks generated by the asparagine and glutamine sidechain NH2 
groups and additional signals from NH containing side chains. [48,49] 
 
 
 
 
 
 
 
 
 
 
Figure 11 Sensitivity-enhanced of 1H/15N HSQC spectra. (A) a dual (15N/1H) inverse CryoProbe 
(Bruker) equipped with a lock and a z-gradient and (B) a conventional triple-resonance 
(13C/15N/1H) inverse probe. Adapted from [50] 
 
The HSQC spectrum provides an overall map or fingerprint of the protein 
target and serves as the basis for assessing ligand binding and the overall fold 
and behavior of a protein. This experiment is fast and easily interpreted but 
requires isotopic labeling of the protein with 15N because of its low natural 
abundance (0.37%). When labeling is not practical, a 1H-13C version of the HSQC 
can be performed. [50] 
As the SAR by NMR method is only applicable to small biomolecules, 
many small proteins or protein domains may fit in these criteria and may serve as 
drug targets, so an important role must be given to the methodology. Transferred 
NOE’s are often employed as one of the final steps in the SAR by NMR method, 
when sequential assignments of the labeled protein target are known, to 
determine the orientation of two adjacently bound ligands to a protein target. 
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Overall information is so useful that major drug companies owe a great 
percentage in their leads to NMR-based screening. [42]  
Although the number of compounds screened at a time is limited by the 
NMR sensitivity, it can be overcome to some extent by using cryoprobe and the 
method is not amenable to very large proteins but this situation can offset by 
using selective labeling. [44,45] 
 
3.4. WATER SUPPRESSION – DOUBLE PULSE FIELD GRADIENT SPIN ECHO 
Hwang and Shaka (1995) first purposed a scheme for water eradication 
based on magnetization [51], using a selective excitation as an approach to 
remove the water signal delivering a pure phase spectra with flat baselines. 
Based on the WATERGATE technique, and starting with the simple pulse 
field gradient spin-echo (SPFGSE) [G - S - G] scheme, where S stands for the 
unitary transformation caused by the selective pulse and assuming that the 
gradients are matched in strength and duration, and are sufficiently strong. With 
further advances they discovered the double pulse field gradient spin-echo 
(DPFGSE) [G1 - S - G1 - G2 - S - G2] will return any transverse magnetization to 
it’s original position attenuated by the square of the probability that a spin is 
flipped by S. [52] 
The suppression of bulk water is achieved with two hard pulse sequences 
90ºx - G1 – 90ºx – T – 90ºx - G1 - G2 – 90ºx – T – 90ºx - G2 with t=500 µs, and 
without the phase roll and other optimizations a good water suppression may be 
expected. The DPFGSE scheme also features the substantial loss of intensity of 
the peaks with chemical shifts near to the water resonance due to a gradual spin-
flip profile of the selective pulse used as an inversion sequence. In order to get a 
better and more selective excitation profile further pulses and delays may be 
added. 
The way the sequence works (see Figure 12 to follow the magnetization) 
is quite simple: the first gradient pulse defocuses all magnetization, while the 
second one just refocuses that magnetization which has been selectively 
inverted, as the remaining magnetization keeps defocusing through this second 
gradient pulse. Comparing simple and double echo, the excitation profile 
reflecting inversion profile of the 180º selective pulse of the spin-echo has no 
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dispersive component, but using a simple rectangular selective pulse, the 
DPFGSE leads to a better excitation profile, that may be explained by the 
probability of a spin flipping which dictates the amplitude of the response. 
 
 
 
 
 
 
 
 
 
 
 
 
From the scheme used with G1 and G2 as the gradients of the same 
magnitude and length, and !1 and !2 the de-phasing produced by the gradients, 
this theory can be visualized in a vectorial model12 – figure 3 -  for a better  
After the first echo G – S - G, the inverted magnetization is not correctly 
refocused, leading to an error ", but after the second echo this phase 
discrepancy " is added again and therefore compensates the first one and the 
magnetization is perfectly refocused and returns to its starting point. 
The usage of more selective pulses would discard the use of double-echo 
in the excitation sculpting scheme on the suppression of the water signal, but this 
scheme can be inputted to an infinite set of NMR experiment sequences.  
 
 
3.5. SATURATION TRANSFER DIFFERENCE (STD) NMR  
The efficiency and simplicity of the STD experiment and its applicability to 
several 1D and 2D NMR sequences gives a great range of data types to be 
acquired, giving this technique first reported by Mayer and Meyer a crescent 
popularity. [17] 
Figure 12. Behavior of transverse magnetization under the application of DPFGSE. The angle " 
is associated with imperfections of the selective inverting procedure S. The angles !1 and !2 
stand for dephasing due to gradients G1 and G2at a given sample location.12 
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The STD protocol gives a spectrum resulting from the subtraction of two 
spectra: a 1D 1H reference spectrum (off resonance), where the saturation is 
applied to a region where no resonances appear, usually at 30 ppm; and a 1D 1H 
(on resonance) where selective saturation is applied to the receptor during a 
certain saturation delay, where no resonances appear but the ones from the 
receptor, usually at 0 or slightly negative ppm’s, but if no ligand peaks exist in the 
low field region, the saturation field may be placed there. In this way we 
guarantee the same amount of input energy in both cases. Only the compounds 
in the mixture that effectively bind to the receptor remain visible in the so called 
STD spectrum. This characteristic presents the possibility to discriminate from a 
mixture of many possible binding compounds to a unique receptor, those which 
effectively bind the receptor and besides this screening (of many different 
potential binding compounds) the scrutiny of the ligand binding epitope is 
possible. [17-19, 53,54]  
The easy and fast STD-NMR assay experiment could use as receptor a 
protein or macromolecular complex of high molecular weight, as well as 
ribozymes or any other possible receptor compound allowing the use of the STD-
NMR experiment in drug-design projects as the main proteic targets are usually 
large dimensioned. A slow tumbling and large correlation times (Tc) by large 
dimensioned proteins and fast rates of relaxation by the proteic system of protons 
tightly coupled by dipole-dipole interactions allows the quantitative interpretation 
of the spectra. [55] 
After a narrowed region of the broad protein resonance is selectively 
saturated, the saturation is spread to all protein protons via spin diffusion and the 
bigger the protein and denser its proton matrix is the more efficient the saturation 
applied is transferred. In a mixture of multiple ligands the complex ligand-receptor 
assembly with those ligands who are capable of bind which will suffer 
intermolecular transfer of magnetization by relaxation via the nuclear overhauser 
effect because when the complex is formed, the small ligand acquires the 
properties of the large macromolecular complex, having high correlation times 
and relaxation rates. This mean that the ligand protons progressively become 
saturated, and so, when the bound ligand molecule dissociates from the complex 
the saturation is brought to the solution in the free state ligand. Having very short 
correlation times and small relaxation rates, the ligand that actually binds to the 
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receptor keeps the saturation for longer periods of time, making possible the 
creation of a crescent pool of saturated free ligands in the solution which will rise 
up in a well resolved STD spectrum – Figure 13 and 15. 
 
 
 
 
 
 
This assembly of a ligand-receptor complex being the basis of the STD 
protocol the determination of KD values using this technique is possible if the 
values lie between 10-3 and 10-8 M. For KD’s values higher than 10-3 M the ligand 
interaction is not tight enough magnetization transfer to occur, once the ligand 
dissociates before it gets saturated, and therefore no STD effect will be visible, 
on the other hand if the KD value is below 10-8 M the ligand remains on the 
complex and does not contributes to the pool of saturated labeled ligands, 
resulting in a slow ligand-receptor complexation turnover, on the established STD 
timescale. [18] 
The pool of saturated labeled ligands grows as new unlabeled ligands bind 
to the saturated receptor and bound ligands dissociate from the complex. 
Figure 13. Detection of binding using the STD technique experiment. Frequency selective 
irradiation (lightning bolt) causes selective 1H saturation (red shade) of the target receptor. 
Irradiation is applied for a sustained interval during which saturation spreads throughout the 
entire receptor via 1H-1H cross-relaxation (spin diffusion). Saturations is transferred to binding 
compounds during their residence time I the receptor binding site. The number of ligands 
having experienced saturation transfer (hits) increases as more ligand exchanges on and off 
the receptor during the sustained saturation periods. Non-binding compounds are un-affected. 
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Therefore a large ligand excess increase the probability of new unlabeled ligand 
becoming available to bind the receptor, and not the already labeled ones, so an 
increase of saturated labeled ligands released into solution is expected. 
The saturation from the receptor is transferred to the compounds via 
cross-relaxation, and, obviously, the protons closest to the receptor become 
more saturated than those that don’t bind directly to the receptor and just have a 
role on complex stabilization. This saturation transference is proportional to 1\R6 
where R is the distance between two protons one for the receptor and one for the 
ligand, so the shorter the spatial distance from the proton to the receptor, the 
higher the intensity in the final STD spectrum is, and the proton with small or no 
contact with the receptor only receive a saturation by spin diffusion leading to 
much reduced signals – Figure 14. This profile makes possible the mapping of 
the binding epitope on the ligand after the ligand-receptor complex becomes 
dissociated, also known as Group Epitope Mapping (GEM) which, as well as 
other STD-NMR potentialities, will be discussed further. 
Figure 14 Illustration of GEM for a ligand in a fast exchange between the bound and free state. 
Irradiation of the protein at a resonance where no ligand signals are present leads to a selective 
and very efficient saturation, which is transferred to the binding parts of the ligand by 
intermolecular saturation transfer. Here, groups presented by larger protons symbolize groups 
in closer contact with the protein and the smallest the ones with few or o contact. Therefore, the 
degree of saturation of the individual protons of a small ligand molecule reflects the proximity of 
these to the protein. 
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Figure 15. Schematic diagram depicting difference spectroscopy in the STD experiment. A - 
an off-resonance experiment (reference) applies rf irradiation away from the receptor and 
ligand protons (blue shade) havind the sectra intensity called I0. B – an on-resonance 
experiment, the rf irradiaction selectively saturates receptor and any binding compounds (red 
shade), this manifests the decreased signal intensity called ISAT. C – the STD response is the 
spectral difference ISTD = I0 – ISAT, which yelds only resonance of the receptor and binding 
compounds. 
As was stated before, to execute a STD experiment we need an on-
resonance spectrum, whose peak intensities are referred as ISAT, and after the 
delivery of saturation, whereas the resonances that suffered saturation transfer 
will decrease their intensity in the spectrum and resonances from non-binding 
ligands or remotely binding to the receptor maintain the same intensity. The off-
resonance spectrum acquired in the same conditions with the saturation 
delivered far from the spectral region observed, gives a standard proton 
spectrum with peak intensities termed as I0. The subtraction of these two spectra 
gives a proton spectrum with peak intensities referred as ISTD. As only the binding 
ligands will show positive peaks on the difference spectrum the STD effect is 
quite simple and easy to observe – Figure 15.  
 
 
 
 
 
 
 
 
 
The NMR pulse sequence – Figure 16 - responsible for the reported effect 
presents a first pulse block sculpting to selective saturate the protein in a user 
defined time, with a train of Gaussian shaped pulses applied n times during the 
saturation transfer delay (xferdly) usually set to 40. [18] The strength of the 
pulses referred to deliver a good STD performance must be of 86 Hz [(!/2") B1 = 
86 Hz]. 
The sequence also features a delay time d1 before the saturation 
assigned to an additional relaxation delay set according to the sample 
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specifications; after the Gauss cascade of pulses the observer pulse is applied, 
the hard 900 pulse applied to whole spectral width region will hit all ligands and 
receptor protons, and by the difference characteristic of this technique, also the 
saturated receptor will show peaks on the STD spectrum. To avoid this non 
desirable situation, and for ligand peaks to emerge more quickly, resolved and 
clearly from noise, we eliminate protein signals by adding a T1p filter (R2 filter), 
also known as spin-lock or trim pulse that stop the evolution of the system 
magnetization and makes a complete transverse relaxation of the receptor, since 
signal protons in large molecules return to the equilibrium faster than in small 
ligands. Thus, at the acquisition time given only the ligand resonances remain 
phased and will appear in the final spectrum. The calibration of this trim pulse 
depends on the time needed to a complete relaxation of the receptor protons and 
the length must not exceed it because otherwise we will progressively decrease 
ligand intensity with further relaxation. 
Completing our sequence we have the DPFGSE excitation scheme 
(already described) to eliminate the water signal from the spectrum and the 
subtraction of the on and off-resonance spectra is accomplished by phase 
cycling.  
 
 
 
 
 
 
 
 
 
2.3) STD experimental approaches  
This flowing subsection will present all the experimental potentialities of 
the Saturation Transfer Difference technique, how to handle spectra for the 
maximization of the data obtained and what new perspectives are being offered 
to the scientific community over the last few years. 
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This brief summary of the approaches used in this current work aims at the 
explanation of how and how far STD-NMR can be stretched and accomplish 
success in its protocol. 
 
3.5.1. SCREENING OF LARGE LIGAND LIBRARIES  
 
Since the very first references on STD-NMR, the possibility to rapidly 
screen up vast libraries of potential ligands for a common receptor was made an 
hallmark. It was possible, from a given pool of possible ligands, to identify the 
ones that actually bind to a common receptor. They will be the exclusive ones to 
appear either on 1D or 2D STD experimental spectra, helping in such way to a 
more effective the drug design and optimization. 
This STD approach was first introduced by Vogtherr and Peters, who 
functionally screened a library of 20 randomly chosen O-Methylated 
galactopyranosides and successfully discriminate them, from a common sample 
containing Sambuncus nigra agglutinin (SNA), and even with no separation or 
purification. Despite the hard task of full NMR assignment and discriminating of 
overlapped peaks, ultimately STD revealed itself to be a robust method to detect 
specific and targeted oriented ligands. More recently it was used to study non-
covalent interactions between different glycostructure transforming enzymes and 
select substrates and products (Fig. 17). Undoubtedly, STD-NMR became a 
methodology with great interest in many different scientific research areas, due to 
its effectiveness and short timescale results, especially between large 
biomolecules and carbohydrates. [56] 
 
 
 
 
 
 
 
 
Figure 17.!STD NMR spectra recorded during CtXR (10 mM) catalyzed and NADH (10 mM) 
consuming reduction of xylose (10 mM) to xylitol. After a 1H NMR spectrum recorded at the 
start. Adapted from [56] 
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3.5.2. TWO-DIMENSIONAL (2D) STD 
 
The uni-dimensional STD sequence can be added to any 2D NMR 
experiment, and we can enhance the STD characteristics on any 2D experiment, 
one all need is to compile the sequence.  
Since peak intensities reflect ligand-protein proton proximity, it is possible 
to determine the binding epitopes, once the closest protons will appear firstly with 
the zooming in on the 2D spectrum. By keeping zooming in, the less intense 
peaks will start to show up too, characterizing the epitope. 
The possibility of such STD associations makes this technique very useful 
in the scrutiny of ligand-receptor interactions at an atomic level, and more 
recently the first example of peptide–protein heteronuclear two-dimensional (2D) 
STD-NMR was reported. [57] 
The first 2D STD-NMR study demonstrated with glycopyranosides and 
agglutinin reported no 2D approach to peptides. So the possibility of 2D 
heteronuclear edited STD NMR study provides information beyond that available 
from 1D 1H STD NMR by greatly reducing signal overlap. The previous 1D STD 
NMR experiments suffered indeed from resonance overlap that makes it very 
difficult to obtain any significant detail beyond identification of each amino acid 
involved in the interaction. Therefore, 2D STD-HSQC NMR acquisition (Fig. 18), 
was employed to observe more detail of the interaction. This technique has 
1
Figure 18. 13C-STD-HSQC data for A20-FMDV2/integrin !v"6 inter- action. (a) 2D STD NMR 
control (off-resonance) spectrum, and (b) 13C-STD-HSQC difference spectrum. Labels in (a) 
show minor interacting residues identified in (b), whereas labels in (b) show significant 
interactions. [57] 
2
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proved to be extremely powerful in the study of protein–peptide interactions, 
especially in the case of interaction of a 21-mer polypeptide with the 186 kDa 
heterodimeric integrin !v"6, where complete 13C and 1H NMR assignments were 
obtained for the peptide under identical conditions to the STD experiments to 
allow STD analysis. 2D 13C-edited STD NMR experiments use a modified HSQC 
experiment with the ability to add or subtract transients depending on whether 1H 
saturation is on-resonance at -3.0 ppm or off-resonance at -30.0 ppm following a 
2 s selective saturation pulse.  
The 2D method has identified 12ValHb and 13LeuHg1/g2 as possessing 
the largest STD amplification factors with the primary interaction involving 6Leu, 
10Leu, 12Val and 13Leu. These observations differ from the original 1D data 
where 12Val was judged to have a lower percentage STD amplification than 
10Leu, 11Gln and 13Leu, and with 11Gln scoring more modestly in the 2D STD 
NMR experiment. Furthermore, the C-terminal amino acids 15Gln-20Thr, that 
were thought to be significant contact sites in the original experiments, are also 
shown in a more modest light with the 2D data. These differences illustrate the 
challenge and effects of signal overlap in peptide based 1D 1H STD NMR that 2D 
heteronuclear STD methodology can circumvent, and a more efficient epitope 
characterization may be done, as presented (Fig. 19). 
 
Figure 19.!Structure of A20-FMDV210 showing (a) significant amino acids highlighted by 2D 
STD NMR and (b) the solvent accessible surface colored as a percentage of the maximum 
STD transfer to highlight significant interactions along the helix. [57] 
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Orientational information regarding peptide–integrin binding can be sought 
from 15N-edited 2D STD NMR that provides STD information regarding the 
peptide backbone. 2D 15N-edited STD NMR experiments were performed by 
collection of separate Io and Isat datasets in an equivalent manner to protein–
protein cross saturation experiments to minimize observed phase artifacts. [58] 
Phase artifacts are due to low saturation transfer efficiency caused by the 
relatively large distances between target protein 1H nuclei and bound peptide 
backbone 15NH groups. 
The 2D STD NMR approach has allowed the confirmation the dominant 
leucine interaction within the Asp-Leu-Xxx-Xxx-Leu (DLXXL) motif in addition to 
observing minimal transfer to the RGD motif, as well as, for the first time, the 
significance of the interaction of Val12, suggesting a different peptide orientation 
for binding to the integrin compared to the TFE (Trifuoretanol) induced structure 
of the peptide. [57] 
As we can see, this successful application of 2D STD NMR has proved 
that this methodology has potential to understand the molecular details of 
peptide–protein interactions, particularly involving protein targets without known 
structures, and it is indeed, a major breakthrough. 
 
 
3.5.3. CHARACTERIZING THE BINDING EPITOPE 
 
Once a ligand interacts with a binding site on the receptor, different 
distances separate the ligand protons from it, and those that are physically 
closest became more saturated due to the STD protocol, which also allows 
discriminating between the closest protons using the intensity manifested on the 
final STD spectra. After the peak assignment is done the peaks with the greater 
percentage of intensity reduction are the ones closest to the protein. Using the 
fraction ISTD/I0, being I0 intensity on the reference spectrum and ISTD the intensity 
of the different peaks in the STD spectrum, we normalize the peak with greater 
reduction to 100 % and other peaks follow this normalization. [60]  
Such protocol may be used to map different kinds of interactions, and in 
this way one knows how the ligand binds to its receptor. 
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To obtain enough data for a GEM characterization a single STD spectrum 
is needed, and if the signal to noise ratio and the saturation transfer is good this 
normalization protocol delivers very accurate and quick maps of interaction of 
ligands with the binding site. So it is possible to say what proton and/or what 
region of the ligand binds primarily to the receptor to be studied. [61] 
 
 
3.5.4. DISSOCIATION CONSTANTS ESTIMATION 
 
The direct estimation of KD values is also possible with this technique, 
although the values have to be between 10-3 M and 10-8 M for reasons already 
explained in the previous section. 
The STD signal area increases directly with the increase of the number of 
molecules that received the saturation transfer in the given delay, thus, one of the 
ways of increasing this effect is to provide a great ligand excess, so that the 
probability of a saturation-free ligand binding the receptor will be higher, obtaining 
a greater pool of saturated ligands free in the solution. 
The outdated way of obtaining a KD value of a ligand is via titration of the 
ligand with a constant concentration of the receptor, and a new parameter was 
introduced by Mayer and Meyer, the STD amplification factor (ASTD). This 
parameter makes possible the higher accuracy for the real value magnitude. This 
STD parameter is defined by the product of fractional saturation of that given 
proton by the ligand excess over the protein, giving a more trusty value of the 
direct protein-receptor interaction. So, if we get an ASTD of 4, it means that the 
Figure 20.! One-dimensional 1H NMR (top) and saturation transfer difference (STD) NMR 
(bottom) spectra of a 0.82 mM La(DOTA- Gal) and Summary of the characterized binding 
epitopes with saturation transfer difference (STD) values relative to H3 as a percentage. [61] 
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STD signal intensity in the ligand is 4 times higher than proton in a protein. Being 
the ASTD a normalization it allows a direct comparison between corresponding 
resonances of a ligand in two different samples, and may also be used as a 
measure of the amplification of the protein observed in the STD signals of the 
ligand. The I0-ISAT is the intensity of the signal in the STD spectrum and fractional 
STD effect given by (I0-ISAT)/I0, I0 being the absolute area of the signal in the 
reference spectrum and ISAT the absolute area of the same signal in the on 
resonance spectrum, which may increase or decrease.  
Since the STD signal intensity increases with the ligand excess, it might be 
hard to understand why the absolute value could decrease, so the explanation 
follows; although more molecules of ligand suffer the saturation transfer, at high 
ligand concentrations the ratio between saturated and total ligands decreases. 
The multiplication of (I0-ISAT)/I0 by the ligand excess (ligand concentration over 
protein concentration) gives the ASTD (see Equation 1). Plotting ASTD against total 
ligand concentration results in a standard one-site drug-responsive type of curve. 
This protocol makes possible the screening of saturation profiles on binding sites.  
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As the ligand excess increases, the ASTD become higher and therefore the 
discrimination between protons that directly contribute to ligand binding and 
those who are only involved in the stabilization and have little or no contact with 
the protein, was made easier. Nevertheless a higher saturation delay also gives 
more saturated ligand molecules, leading to a greater ASTD, but with implications 
discussed on the next section. 
Lepre and Peng studied the determination of KD values based on titration. 
The ISTD can be written as ISTD= C!STD[EL], where C is a proportionality constant 
that makes the appropriate unit conversions,  !STD is a dimensionless scaling 
factor that represents the maximum STD amplification. The reference I0 is just 
proportional to LT, and so the fractional STD effect can be written as ISTD/I0 = " 
[EL]/LT = !STD PB = PBE and " is the ligand excess (LT/ET), and we have equation 
(2) where PB is the bound ligand fraction [EL]/LT and PBE is the fractional 
occupation of the binding site by ligand L. [31] 
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This equation reminds the well-known equation of Henri-Michaelis-Menten 
enzymatic reaction rate v0: 
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So to estimate the KD value for a given ligand-receptor interaction it is only 
necessary to fit the ASTD values across the titration of the ligand resonances to 
equation (2), the lowest KD value is taken as the more accurate result. 
Another method developed by Cheng and Prusoff using a known inhibitor 
on a competitive STD experiment also made possible the determination of the 
dissociation constant. Using equation (3) where IC50 is the value where 50% of 
the protein is inhibited by I with a known KD value, the ligand KD is readily 
obtained in a single experiment. [62] 
 !! ! !!!!!!"!"#!! !    (4) 
 
The STD-NMR technique once again gives different possibilities to be 
acknowledgement of the nature of the binding site, and secondary binding sites 
or allosteric changes must be a never to forget factor, being an approximation the 
results obtained are quite relevant.   
 
3.5.5. THE BINDING ISOTHERM OF STD INITIAL GROWTH RATES 
 
Direct approaches have failed to give correct values of equilibrium 
dissociation constants (KD) from STD NMR spectroscopic titrations, since it has 
been demonstrated that the magnitudes of the determined constants depend on 
the particular STD user defined signal of the ligand chosen to build the 
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corresponding binding isotherms. Leading to of a relatively large uncertainty that 
might be inherent to the determination of KD by STD NMR spectroscopy, 
precluding the use of this technique for accurate measurements of protein–ligand 
affinities in solution. 
In 2010 Angulo and Nieto presented a protocol to accurately solve STD 
NMR quantitative studies of protein–ligand interactions, some of which involving 
multimodal binding ligands on one binding site, in which STD intensities can be 
perceptively affected by ligand cross-rebinding processes. They have shown that 
such multimodal systems can be quantitatively treated by an appropriate analysis 
of STD NMR experiments based on STD initial growth rates. Thus, the 
experimental system can be deconvoluted as a simple sum of the contributions 
from each mode. 
This approach is justified by considering the effects of fast ligand rebinding 
during the receptor saturation in the STD experiment. If there is a certain 
probability that a given ligand molecule reenters into the binding site after a 
preceding binding event (and this rebinding is fast enough related to the 
relaxation properties), then the ligand spin populations would be partially 
perturbed due to the previous transfer step, and hence, its capacity to receive 
more transfer of saturation from the receptor will be different from that from a 
fresh ligand molecule. Consequently, the amount of magnetization transferred to 
the free ligand would be smaller. The rebinding process in STD has not been 
considered before, probably because typical experimental conditions for standard 
STD NMR spectroscopy (i.e., for binding detection, screening, and determination 
of group epitope mapping) disfavor ligand rebinding because it uses high ligand-
to-protein ratios. In contrast, protein–ligand titration experiments can involve 
large fractions of bound ligand, in the low ligand-to-protein ratio regions of the 
experimental isotherm, increasing then the likelihood of rebinding events. Indeed, 
we demonstrate herein that rebinding is one of the main causes of errors in the 
determination of affinities by STD NMR spectroscopic titration experiments.  
The apparent KD obtained be previous titration methods were prone to 
output a wide range of values. In the dependence of the saturation time of the 
binding of chitobiose to WGA using ASTD from STD NMR spectroscopic titrations, 
as a function of the saturation time (tsat) it was reported a range from 300 to 730 
µM, at 1 and 4 seconds, respectively.  For the proton chosen in the case of L-
!!
!
"#!
Tryptophan binding to bovine serum albumin (BSA) the values obtained, for 
example, at saturation time of 4 seconds, ranged from 3300 to 1060 µM. So a 
resolution to normalize parameters, such as, saturation time and fraction of 
bound ligand were planned and proposed by them. [33] 
To take in order these considerations a protocol was done by constructing 
a binding (Langmuir) isotherm as a function of the ligand concentration in the 
sample using the initial growth rates of the STD amplification factors (ASTD-0), 
instead of the ASTD factors at a given saturation time. The initial growth rate 
corresponds to the ASTD value at the limit of zero tsat, when virtually no ligand 
turnover takes place, therefore, avoiding the potential effects of fast protein– 
ligand-rebinding processes. The growth of STD-AF values with saturation time 
can be appropriately described by a monoexponential asymptotic equation, 
equation 5.  !!"# !!"# ! !!"#! !"# !! !"#!!!!!"#! !!"#!             (5) 
 
in which ASTD-max represents the maximum ASTD achievable for a given proton 
(i.e., for very long saturation times), and ksat is its saturation rate constant. After 
this first fit, the initial slope (ASTD-0) is easily obtained by the product ASTD-max by 
ksat. Afterwords, and to finalize the protocol, the initial slopes are represented as 
a function of the ligand concentration, and the mathematical fit to a Langmuir 
isotherm (y=Bmax X/ (KD+X)) is carried out. [33] 
The analysis of the saturation rate, ksat, provides additional evidence for 
the presence of fast rebinding. This parameter, that determines how fast the 
plateau of the ASTD build-up curve is reached, is not constant throughout the 
titration, decreasing with ligand concentration (Figure 21). This means that a 
steady-state is reached at shorter saturation times for low ligand concentrations, 
as a consequence of the decrease of maximum STD-AF caused by rebinding. 
Moreover, different build up rates may lead to a detection of most 
saturated proton, when it is not, but the one, after a long saturation time, that 
reached a higher plateau, due to spin diffusion or cross relaxation. [33] 
 
 
 
!!
!
"#!
 
 
 
 
 
 
 
 
 
The similarity of KD values obtained from the ones reported by different 
analytical methodologies gives a very good status for this protocol, which, and 
after taking a second look, takes 4 times the original time in a original titration, 
but yields accurate proof of the importance of following it for further studies of 
protein-ligand interactions in a quantitative manner.  
 
3.5.6. COMPETITIVE STD  
 
The first order kinetics adopted by the STD amplification factor on the 
ligand-receptor interaction revealed a new assay based on the interaction of two 
ligands with different dissociation constants to the same receptor, the so-called 
“competitive STD”. First of all the limitation on KD ranges known for the standard 
STD may be overcome based on the reduction of the ISTD of the ligand fitted on 
the given range (10-3 M to 10-8 M). The ISTD will be as high as the amount of 
protein available to dock the ligand and transfer the saturation applied. So, in a 
mixture of competing ligands, the available binding pocket will decrease and the 
ligand with the lowest KD, which will leave less binding pockets available, will 
decrease the relative intensity of the ligand with lowest affinity.  
The protocols adopted for the estimation of small dissociation constants 
include an initial STD spectrum acquisition with the ligand in study, then addition 
Figure 21.!The binding isotherm of STD-AF initial growth rates approach. The new protocol 
for protein–ligand affinity measurements by STD NMR spectroscopy is illustrated for the L-
tryptophan–BSA system. a) For each ligand (l-Trp) concentration (0.2 (!), 0.4 ("), 0.6 (!), 
0.8 ("), and 1.0 mm (#)), ASTD values) are obtained at different saturation times (1,2, 3, and 
4 s) and fit by using the equation 5. b) The initial slopes are represented as a function of the 
ligand concentration, and the mathematical fit to a Langmuir isotherm, delivering the 
thermodynamic KD value. 
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of determined concentration of the competitor and finally to obtain a new STD 
spectrum in the same experimental conditions.! Accurate KD values have been 
determined by competition studies, in which the unknown KD of a ligand is 
determined by monitoring its displacement from the protein binding site while a 
reference ligand of known affinity is titrated over the same sample, using the 
Cheng–Prusoff equation. [62] 
The unknown constant of the competitor will be calculated based on the 
reduction of the ISTD of the ligand with the known KD using equation 6. 
 
     (6) 
 
 
 The fact that the discribed protocol will lead to a small amount of time 
needed to depict the stated principles helped STD-NMR technique to become a 
very powerful tool in this type of study of ligand-receptor interaction, especially 
when compared with non-spectroscopic assays. After the, sometimes troubled, 
task of peak assignment is done, the potentialities clearly rise up in this 
challenging study. 
 This competition STD NMR approach can also be used for compound 
library screening of ligands over a wider affinity range including high-affinity 
ligands that would be missed by the STD NMR method.  
 
 
  
 
 
 
 
 
 
Figure 22.! Application of competition STD NMR to screen a compound mixture. (A) 1D proton 
spectrum of a weak ligand, 6-CH3-D,L-Trp !95 µM) used as an STD indicator, in the presence of 5 
µM HSA; (B) the corresponding STD NMR spectrum; (C) 1D proton spectrum of a compound 
mixture including 6-CH3 -D,L-Trp (95 µM), 7-CH3 -D,L-Trp (90 µM) and diazepam (15 µM) with 5 
µM HSA; (D) corresponding STD NMR spectrum. [63] 
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In the example given by Wyss et al (Fig. 22), a substantial reduction in the 
STD signal intensities of 6- D,L-CH3-Trp was observed, which indicates the 
presence of an active ligand in the mixture. A new STD signal appeared at 3.45 
ppm and matches the methyl signal of diazepam, identifying diazepam as a 
ligand. The absence of STD signals from 7-CH3-D, L-Trp is consistent with the 
fact that it does not interact with the protein. The observed fractional reduction of 
the STD signal intensities of the 6- CH3-D,L-Trp methyl group in the presence 
and absence of diazepam was 0.41. The dissociation constant of diazepam was 
estimated to be 2.4 µM, which agrees well with the value of 2.6 µM reported in 
the literature. We can see that the STD signal intensities of 6-CH3-D,L-Trp were 
reduced, the STD signal for the methyl signal of diazepam at 3.45 ppm was 
observed and no STD signals of 7-CH3 -D,L-Trp were detected. [63] 
 
3.5.7. STD ADVANTAGES AND LIMITATIONS  
The STD technique is based on the NOE effect and comparing it directly 
with the tr-NOE technique that used 2D NOESY experiments which take typically 
4 hours against the 0.5 hour of STD acquisition we can see clearly that, as a 
screening technique, 1D STD overcome tr-NOE. Moreover the crowded 2D 
NOESY makes the discrimination of inverted peaks a difficult task. 
The WaterLOGSY experiment when used in a mixture of several ligands 
with overlapped chemical shifts makes also the spectroscopist burden heavy 
because it becomes very hard to distinguish on each ligand, especially if 
compared with STD, where only binding ligands manifest their presence in the 
final spectrum. 
The total amount of protein required for an acquisition may vary, 
depending in protein cost and the capacity of delivering good STD spectra with 
protein concentrations in the nano molar range an extra positive point to this 
technique can also added. 
The STD methodology is based on the dipole-dipole interactions of the 
saturation transfer from receptor. This will work just fine on a receptor with a 
dense proton matrix, such as proteins, but if the work uses for example RNA 
strands as a receptor, which has a low intrinsic proton density, STD may not 
!!
!
"#!
result so effectively. The WaterLOGSY method may be used to overcome this 
aspect, since the water molecules that surround RNA strand compensate the 
lack of proton density and therefore is will still be possible to maintain the spin-
diffusion and cross-relaxation needed for a good final spectrum. 
We can never forget the STD applicability to an almost unlimited number 
of NMR techniques and having the cascade of selective pulsed added on any 
NMR experiment we will have the corresponding sequence effect with the 
inclusion of the STD features. 
The dissociation constants are just an estimation of the real value and 
other approaches may help to this determination below the range values stated 
throughout this work. 
Finally we can say that STD methodology allow us the identification of 
ligand binding epitope, and will work for any large protein with a dense proton 
matrix, it doesn’t require an isotope labeling, has a very reasonable timescale for 
the data obtained and even the limit on KD ranges may be enlarged. 
 
3.6. DOCKING SIMULATIONS 
 
The computational techniques used in drug discovery utilize rapid in silico 
assessment of large libraries of chemical structures in order to identify those 
structures that are most likely to bind to a drug target, typically a protein, receptor 
or enzyme.[64] 
 Significant progress has been made in structure based drug design by 
pharmaceutical companies at different stages of drug discovery, such as 
identifying new hits, enhancing molecule binding affinity in hit-to-lead, and 
reducing toxicities in lead optimization. In silico methods based on molecular and 
quantum mechanics, such as docking, molecular dynamics and ab initio chemical 
reactivity calculations, bring us closer to understand drug metabolism and predict 
drug–drug interactions, predict drug regioselectivity, stereoselectivity, reactive 
metabolites, induction, inhibition and mechanism-based inactivation, as well as 
their implementation in hit-to-lead drug discovery. 
 The goal of drug discovery is to find the best medicines to prevent, treat 
and cure diseases quickly and efficiently. To fulfill this goal, computational tools 
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have helped medicinal chemists modify and optimize molecules to become 
potent drug candidates, have led biologists and pharmacologists to explore new 
disease genes and novel drug targets, and have been also guiding drug 
metabolism scientists to achieve better pharmacokinetic profiles and avoid drug 
toxicities. [64] 
These in silico approaches have been widely applied to predict drug 
absorption, distribution, metabolism, excretion and toxicity (ADMET). The 
optimization of chemical space in early discovery stage using in silico tools will 
shorten the total drug discovery cycle time and at the same time enhance the 
late-stage drug survival rate (Fig. 23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. General workflow for ensemble-based virtual screen experiment. Blue arrows indicate 
size of data sets (i.e. increasing or decreasing) at each step; * denotes emerging methods that 
have not yet been tested. (AMD: accelerated molecular dynamics, GB MD: generalized Born 
molecular dynamics, RMSD: root-mean-square-deviation, ZINC – ZINC Is Not Commercial, ACD: 
Available Chemical Database, NCI: National Cancer Institute, MM-PB(GB)SA: Molecular 
Mechanics – Poisson-Boltzmann (Generalized Born) Surface Area). 
 
!!
!
"#!
In silico drug metabolism prediction methods are ligand-based such as 
building pharmacophore and QSAR quantitative structure–activity relationship 
(QSAR) modeling, before structure-based drug design emerges.[65] QSAR 
modeling still plays a big role in pharmaceutical industry because of the 
significant growth of high-throughput screening data. In QSAR, neural networks, 
classification methods such as recursive partitioning, decision trees, and support 
vector machines are constructed with topological, structural and electronic 
descriptors. ADMET properties are thus predicted on the basis of these 
descriptors, such as lipophilicity and solubility. Usually QSAR predictions work 
particularly well with structurally similar compounds, whereas molecules from 
other regions of the chemical space can cause outliers. Furthermore, QSAR is 
limited by the quality of the available experimental data. QSAR can sometimes 
provide hints about the active site if according descriptors appear in the 
regression equation, such as steric constraints and lipophilicity. Pharmacophore 
models are constructed to overlay structures of all ligands also to simulate the 
spatial and chemical properties of the binding site. [66] 
Pharmacophore models, structure-based docking and molecular dynamics 
are all mechanism-based approaches. Recently, the prediction power has been 
improved in building 3D-QSAR [67] – Figure 24 - pharmacophore models with 
spatial atomic descriptors in consideration. These descriptors include molecular 
interaction fields, electronic properties and shapes of active sites. Indeed, 
structure-based modeling by combining molecular and quantum mechanics, 
enables us to predict substrate affinity, lability and metabolic pathways. In 
practice, mass spectrometry, nuclear magnetic resonance spectroscopy, 
proteomics, metabolomics, and other advanced bioanalytical techniques have 
been improved significantly, which can help us validate these in silico predictions 
quickly. 
Water molecules often play an essential role in drug–enzyme interactions: 
the displacement of water molecules from binding site is one main source of 
binding free energy. [68] Water molecules were found in the binding pockets of 
drug-metabolizing enzymes, which can make favorable interactions with either 
ligands or protein active site residues. Therefore, active-site water molecules are 
often included in computational methods as one of the strategies to predict drug 
metabolism.  
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Figure 24. General workflow for 3D QSAR method. 
A continuous time-course structural determination would be an ideal 
method to visualize the dynamic change of active site residues, but still, not 
possible in the current experimental settings. Applying this strategy, the accuracy 
of docking algorithms was significantly enhanced. [68] 
 More rigorous molecular dynamics based approaches to include full 
receptor flexibility are now being applied in larger-scale virtual screening 
applications, thanks in part to steady increases in computational power and the 
development of new and improved methods improving computational efficiency 
of the underlying strategies. [69] 
 Some approaches also approximate binding free energy by adding up 
individual contributions of different interactions. However, the individual energy 
terms are derived from physico-chemical theory and are not determined by fitting 
to experimental affinities. In most cases, gas phase molecular mechanical 
contributions are combined with solvation free energies. Evaluation of solvation 
energy is a challenge both in terms of computational demands and accuracy. The 
methods used to calculate solvation include implicit solvent methods like 
Possion-Boltzmann and surface generalized Born methods. The gas phase 
energy calculations depend on the type of the force field, for example, AMBER 
and CHARMM. 
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 Protein flexibility and the dynamics of intermolecular interfaces can regulate 
binding affinity and specificity in molecular recognition. It has been suggested 
that structural stability and flexibility during molecular recognition are associated 
with the ruggedness of the underlying binding energy landscape and can be 
related to various functions, such as specificity or permissiveness in recognition. 
Hierarchical approaches incorporating both ligand and protein flexibilities have 
contributed to recent progress in ligand-protein docking. Such procedures include 
multistage docking approaches and a hierarchy of energy functions that aim to 
capture the subtleties of protein flexibility upon ligand binding. Two of the best 
programs, and more widely used, for these exhaustive and accurate simulations 
are Autodock and HADDOCK. 
 
3.6.1.  AUTODOCK VINA 
 
The method used in this work for virtual ligand screening, was Autodock 
Vina. This recently developed program improves approximately two orders of 
magnitude speed-up compared with the molecular docking software previously 
developed by the Scripps Research Institute, AutoDock 4.2, while also 
significantly improving the accuracy of the binding mode predictions (Fig. 25). 
These advantages clearly place this program as an excellent docking software. 
[25] 
 
 
 
 
 
 
 
 
 Among the assumptions made by Autodock Vina is the commitment to a 
particular protonation state of and charge distribution in the molecules that do not 
Figure 15. The fraction of the 190 test complexes for which RMSD < 2 Å was achieved by 
AutoDock and Vina; B) Average time, in minutes per complex, taken by AutoDock, single-
threaded Vina and Vina with eight-way multithreading. The time for AutoDock does not include 
the necessary initial AutoGrid run. [25] 
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change between, for example, their bound and unbound states. Additionally, 
docking generally assumes much or all of the receptor rigid, the covalent lengths, 
and angles constant, while considering a chosen set of covalent bonds freely 
rotatable (Fig. 26). 
Importantly, although molecular dynamics directly deals with energies 
(referred to as force fields in chemistry), docking is ultimately interested in 
reproducing chemical potentials, which determine the bound conformation 
preference and the free energy of binding. It is a qualitatively different concept 
governed not only by the minima in the energy profile but also by the shape of 
the profile and the temperature. [25] 
Docking programs generally use a scoring function, which can be seen as 
an attempt to approximate the standard chemical potentials of the system. When 
the superficially physics-based terms like the 6–12 van der Waals interactions 
and Coulomb energies are used in the scoring function (based on AMBER force 
field), they need to be significantly empirically weighted, in part, to account for 
this difference between energies and free energies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26! View of autodock Tools for dansyl sarcosine  when picking the torsion tree for 
molecular structure. 
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Additionally, manually choosing the atom types for grid maps, calculating 
grid map files with AutoGrid, and additional time waiting for this results is no 
longer necessary, as Vina calculates its own grid maps quickly and auto- 
matically. It also clusters and ranks the results without exposing the user to 
intermediate details (Fig. 27). 
A frequently encountered source of issues for AutoDock 4 users has to do 
with the fixed data structure sizes in the program: the maximum number of 
atoms, the maximum number of rotatable bonds, the maximum grid map size, 
etc. These limits are fixed at compile time, and setting them higher might waste 
memory and time. To change these limits to meet their needs, the users are 
required to alter them in the source code and recompile AutoDock 4—a task too 
daunting and error-prone for many users. In contrast, Vina does not have any 
such limitations, for practical purposes. The program adapts itself to the input. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27.! View from Autodock Tools when selecting the grid box to be used in docking 
simulations.  
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All Autodock Vina docking simulations steps can be summarized as: 
- Protein or receptor input in pdb extension and polar hydrogen atoms 
are added to it and the nonpolar hydrogen atoms are merged. This 
can now be saved as receptor.pdbqt. 
- Ligands are open as pdb files and automatically are added gasteiger 
charges, merges non-polar hydrogen, and detects the aromatic 
carbons. We can choose the torsion tree to respect our previous 
knowledges. This can now be saved as the ligand.pdbqt file. 
- After detecting the protons prone to establish the interaction the Grid 
Box is built, and large enough to accommodate the ligand to move 
freely. 
- Finally all pdbqt files are established to configure the run. We have the 
receptor, the ligand and the grid dimensions as well as its coordinates. 
Run the software and expect good results  
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4. MATERIALS AND METHODS 
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4. Materials and Methods 
4.1 SOLUTIONS 
The ligands were complexed with La3+, which was chosen in order to replace and 
simulate the Gd3+, due to its diamagnetic characteristics and similar radius, 195 
and 180 pm respectively. Human Serum Albumin was purchased from Sigma-
Aldrich (ref. A3782), essentially fatty acid free, ~99% (agarose gel 
electrophoresis), lyophilized powder. Ibuprofen and Warfarin were also 
purchased from Sigma-Aldrich. All solutions were prepared in the absence of 
buffer, using deuterium oxide 99,9% 2D, also from Sigma-Aldrich.  
La(BOPTA), DTPACholate and NAFTO-EGTA were received, respectivelly from 
Professors Silvio Aime and Mauro Botta from Dipartimento di Chimica, Università 
di Torino, Itally and Dipartamiento di Scienze dell' Ambiente e della Vita, 
Università del Piemonte Orientale “Amedeo Avogadro”, Alessandria, Italy. 
(DTPA-Cholate) and (NAPHTO-EGTA) were mixed with LaCl3 in a 5% ligand 
excess solution. The pH was adjusted to 10 using NaOD and DCl stock solutions, 
while La(BOPTA), which was already prepared and crystallized, and the pH 
adjusted to 7 using NaOD and DCl stock solutions. The complex solution was 
prepared in 99.9% deuterated water solvent and non-buffered. It was achieved a 
clean homogeneous solution was obtained in all cases. 
The SSS-(!)-[Y.L1]3+ and RRR-(")-[Y.L2]3+ complexes, and N-dansyl sarcsosine 
were received from Professor David Parker from Department of Chemistry, 
Durham University, UK, already in complexed form with Yttrium (III), the pH was 
adjusted to 7 using NaOD and DCl stock solutions. 
HDMPP, Vanadate solutions and vanadium-DMPP complexes were received 
already prepared, at pH around 7, by Prof. Dr. Margarida Castro from 
Department of Life Sciences, Coimbra University. 
 
4.2. NMR STUDIES 
All 1H NMR spectra were acquired using a 3 mm pulse field gradient (PFG) 
inverse probe  (Idpfg_3mm) on a Varian NMRS-600 NMR Spectrometer working 
at 599.72 MHz. For each sample 1D 1H spectra were acquired using all the same 
parameters used for the STD NMR spectra, with exception to the number of 
scans. For 1H spectra 128 to 256 scans were performed while for the STD NMR 
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spectra 1024 to 2048 scans were collected. The acquisition time was set to 2 
seconds, the repetition time was 5 seconds, in the STD experiments a selective 
saturation pulse of 5 seconds was applied over the protein. For the binding 
isotherms an array of selective saturation pulses was done from 0.5 seconds to 5 
seconds. A line broadening of 0.75 Hz, corresponding to the digital resolution 
was used in all spectra for analysis. All spectra were analyzed using MestreNova 
Software v5.1.1-3092.  
For plotting procedure all data treatment was done in GraphPad Prism. 
 
 
4.2.1. The gradient-selected COrrelation SpectroscopY (COSY) 
COSY is a 2D NMR technique that gives correlations between J-coupled signals 
by incrementing the delay between two 90o proton pulses. The resulting 2D 
spectrum is generally displayed as a contour plot, which is similar to a 
topographical map. When looking at a contour map, we are actually looking down 
at a cross-section (slice) of a 3D-image of an NMR spectrum. The usual 1D 
spectrum is traced on the diagonal of the plot and any peaks that are not on the 
diagonal represent cross-peaks or correlation peaks that are a result of J-
coupling. Thus, by simply tracing a rectangle using the diagonal and cross-peaks 
as vertices you will know which protons are coupled to each other. Standard 
COSY experiments require phase cycling to remove unwanted signals and thus 
can be quite time consuming. This can be largely circumvented using gradient-
selected COSY (gCOSY), which utilizes pulsed field gradients to destroy 
unwanted z-magnetization and hence their associated signals (axial peaks). 
Depending on concentration quality gCOSY spectra can be acquired in as little 
as 5 minutes.[71] 
 
4.2.2. Acquiring 2D gCOSY 
First we need to acquire a 1D spectrum and set the spectral width and the offset 
frequency and then when transform it in a gCOSY in Experiments > 2D > 
Homonuclear Correlation Experiments  > gCOSY. The number of scans for each 
FID, in the directly detected dimension (F2) must be inputted regarding different 
solutions, we may increase the number if we have a dilute sample. The number 
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of increments is responsible of defining the resolution in the indirectly detected 
dimension (F1). The more increments and , the higher the resolution is.  
Change 90o pulse to a 45o pulse if you want to decrease the size of the diagonal 
and emphasize active coupling partners. We can also change “tau” = propagation 
time that is usually 0, but we can set it to 0.2 to emphasize long-range couplings. 
If presaturation is desired, set “satmode='y'” and verify that select the frequency 
value previously found in the 1D setup of presaturation.  
After the collection and process of the 2D spectra we can Increase number of 
levels on contour plot using the command “dpcon(15,1.2)”. The “dpcon” flag is for 
displaying the contours. The first number (15, in this case) is the number of 
contour lines (default is 4). The second number (1.2, in this case) is the relative 
spacing intensity (default is 2). 
 
4.3. STD-NMR STEP by STEP 
 
4.3.1. Compiling a new sequence in the system. 
The BIOpack with the DPFGSE and the full NMR sequence came in a .tar.gz 
extension, a normal compacted file from Linux OS. The content is easily 
extracted and we will have the corresponding folders: maclib, manual, parlib, 
psglib and templates. We need to copy their content to the corresponding folders 
in our sytem (normally the path is User/vnmrsys/, this is the main folder for any 
given user). Then join User/vnmrsys/psglib/ folder, and open the terminal with the 
command line of the OS. To generate and successfully complete the sequence 
one must type “seqgen name of the sequence to be installed.c”. This will 
automatically place all of the needed files in our corresponding folders and 
VNMR will be able to recognize all the sequence parameters.  A message will 
indicate the success of the compilation. Open VNMR and the sequence is 
working, if the compilation was successfully achieved. 
 
4.3.2 Setting up the experiment 
 
4.3.2.1 Calibration of DPFGSE for water suppression 
The most common way to calibrate the DPFGSE sequence is to load the 1H 
NMR experiment with the active flag for water suppression. For this, go to 
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Experiments > User Defined > 1D DPFGSE water suppression. To visually 
display the sequence (Fig. 28) one must type “dps” (display sequence) on the 
command line or go to Acquisition tab and select ”sequence” and automatically 
the NMR sequence of the experiment is displayed. 
 
 
Figure 28. 1D DPFGSE NMR sequence as displayed in VNMRJ v2.3A software. Values 
indicated in the Figure are those defined by default. 
 
 Explaining what is visually outputted, the sequence represents the G1 – 
soft180o – hard180o – G1 - G2 –soft180o–hard180o – G2 scheme reported by 
Hwang and Shaka. [51] 
 The selective pulse necessary for selective removal of water resonances 
is termed, in our system,  “W_supp”. As depicted in the above Figure 28, the 
word W_supp appears below the selective pulse, meaning that this is the 
selected pulse shape to be applied. However, if it's the first time this sequence 
block (DPFGSE) is used (say we were running carbon acquisition), it is 
necessary to generate the selective wave since it does not exist by default in the 
system. The software will generate the pulse, calibrating its power to the length 
defined by the user and accordingly to the parameters defined in the probe file for 
90o pulse width (pw) and our transmitter power (tpwr). The selective pulse length 
is defined in the width box of the same menu. A pulse width around 2 ms is 
referenced as a good value. [51] A too short pulse width will be translated in 
insufficient suppression and a too long pulse width will generate J-coupling 
artefacts in the final spectra. So if one has any doubts we might as well perform 
an array for this parameter. 
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 To accomplish this go to the Acquire tab > Pulse Sequence menu and 
click the Recreate Water Refocusing Shape button, after selecting the pulse 
width for the pulse. When the pulse is generated, a big yellow message is 
displayed informing the user that in order to achieve good water suppression only 
the fine power for water reference shape (“wrefpwrf”) parameter could be 
calibrated. The menu and the message are depicted in Figure 29. An array 
calibration protocol, similar to the one used for 90o pulse calibration, fulfills the 
needs of this approach, if desirable. So we search for the value that yields the 
less intense water signal. It is recommended from NMR technicians and 
developers that steady state scans be performed prior to acquisition, for this 
sequence 16-32 should be enough. After correct calibration, the same 
parameters can be used in every sequence that allows DPFGSE, obviously if the 
same probe is used. 
 
 
 
 
 
 
Figure 29. Menu to DPFGSE and the message saw by the user as displayed in VNMRJ v2.3A 
software.  
 
4.3.2.2 The STD experiment 
To load the Saturation Transfer Difference experiment go to Experiments > User 
Defined > Saturation Transfer Difference. We can also display the sequence by 
typing “dps”, the display will show the corresponding NMR sequence. 
First, define the water suppression parameters with the values previously 
calculated and set all the other basic parameters of acquisition to their previously 
optimized values. 
 
4.3.2.2.1. Selective Saturation 
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4.3.2.2.1.1 Pulse Shape 
A Gaussian shaped pulse is standardly defined as selective irradiation. 
Nevertheless, to change the pulse shape type “satshape='shape'” in the 
command line, where shape is the name of the file that defines the shape without 
the .RF extension. Be sure that the shape you select is already created and 
placed in the correct directory. If a non-existent shape is selected the software 
will output no error, and the user might be misled. 
 
4.3.2.2.1.2 Pulse Power 
An important task to accomplish here is the calibration of the Gaussian pulse to 
(!/2¶) B1 = 86 Hz, according to Mayer and Meyer. In our system we add a small 
doubt that was “How to convert Hz in dB?” 
So, and with the help from Varian technician Péter Sándor, we discover the 
“attval” parameter. Once in the command line type “attval(pw90,tpwr)”, where 
“pw90” is and “tpwr” are our own parameters arrayed, if we have a pw of 7 and a 
tpwr of 54 the typing will be attval(7,54) and it will output a Table similar to Figure 
30. 
 
 
 
 
 
 
 
Figure 30. Table to calculate the pulse width in microseconds for a B1 of 86 Hz as displayed in 
VNMRJ v2.3A software.  
 
Search in the Table for the attenuator value that gives a B1 field of 86 Hz. Then, 
type satpwr = B1hz, where B1 in Hz is the value determined by the Table. 
If desired, the pulse width of selective irradiation can be modified with the satpw 
parameter.  
 
4.3.2.2.1.3 Selective saturation Frequency 
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In order to correctly select the desirable frequency to saturate, first acquire a 
normal 1H NMR spectrum, which will show the complete profile of the sample, 
ligands and receptor. Using an 86 Hz Gaussian pulse during 30 ms, a region of 
±15 Hz at 50% amplitude is affected. It is important that resonances are not 
affected at ±150 Hz away from the selected frequency otherwise we could not 
observe the saturation transference effectively.  
Placing the cursor in a region of the spectrum where only protein resonances 
are hit, and no ligand overlay, is the only way we to guarantee a successful 
protocol. Then type “movetof” to that region in the command line and ask the “tof” 
value typing “tof?”. This value is outputed in Hz and will be the one that defines 
the STD saturation frequency. The off-resonance reference saturation frequency 
can be as it is by default, about 16000 Hz, around 30 ppm. One should not forget 
to replace the transmitter offset to its original value, after choosing the selective 
region of saturation. 
 
4.3.2.2.1.4 Spin-Lock Calibration 
Load the “attval” Table again (Fig. 30) and it assess the spectral width, in Hz, 
occupied by the protein. This value is the desired B1 field in Hz. Remember 
considering that half of B1 affects the left side of the transmitter offset while the 
other half corresponds to the right side. Correlate the obtained B1 value with the 
attenuator value and this will be the power applied by the spin-lock pulse. 
Using the 1D DPFGSE water suppression experiment we can now complete the 
calibration of the spin-lock filter, since this experiment also has the spin-lock 
pulse flag. This flag is termed “trim_flg” and can be activated/deactivated. The 
Trim parameter defines the spin-lock pulse width in seconds. This means that it 
must be input in seconds, if 30 ms is the desired value then type in the command 
line trim=0.03. Now, it is only necessary to acquire multiple spectra with different 
spin-lock lengths to find out what is the minimum amount of time required to full 
protein relaxation, for different protein samples. Remember to acquire some 
scans prior to final acquisition, > 16 are desirable, in order to avoid several 
artifacts. 
After the calibration is complete just define the same values in the STD 
experiment. 
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Having completed this protocol, do not forget to also define steady state scans in 
the STD experiment, > 64 are desirable. 
 
4.4. COMPETITION by STD-NMR  
The possible competition for the same binding site of HSA was studied by direct 
displacement of the ligands with the widely known HSA ligands, Ibuprofen, 
Warfarin, L-Tryptophan and N-dansyl sarcosine. These direct competition 
experiments were used primarily to determine the binding site of these CAs in the 
HSA protein according to the level of the displacement relative to HSA and ligand 
alone. 
 
4.5. DOCKING Simulations  
The molecular docking simulations were performed using Autodock Vina 1.1.1. 1 
from the Scripps Research Institute. Autodock Tools 1.5.4 (revision 29) was used 
to prepare all the needed “pdbqt” files for Autodock Vina.   
The HSA structure used for the chiroptical probes was the one with the entry 
2XVQ.pdb, because this X-ray structure contains the N-dansyl sarcosine, for 
which is known to interact with drug site II, and therefore, the adequate model to 
study the possible binding site for our ligands.  
To have the most accurate results over HSAs drug site I and II, two X-ray 
structures were used, both complexed, with the known binders Warfarin and 
Ibuprofen respectively. The entry code in pdb database is 2BXD for drug site I 
and 2BXG for drug site II. With this protocol docking simulations were accurately 
directed to both binding sites and the results are much more accountable than 
with random structures.  
From all structures, containing the different known binders, the chain A was 
selected and polar hydrogen atoms were added to the HSA and its nonpolar 
hydrogen atoms were merged. 
The structure of the chiroptical probes were obtained from DFT energy 
minimization calculations performed previously with Gaussian 03, while all of the 
remaining coumpounds were built in Gaussian 03 software after a clean structure 
spatial arrangement. 
After opening the ligands in Autodock Tools, the program automatically adds 
gasteiger charges, merges non-polar hydrogens, and detects the aromatic 
!!
!
"#!
carbons. Rotatable bonds were set according to the stereochemistry of the 
molecule, maintaining the chelate cage of the contrast agent, and all the other 
possible rotatable bonds were left this way. 
All calculations for fixed protein flexible ligand docking were done using the 
Lamarckian Genetic Algorithm (LGA) method. The GRID box parameters used 
were:  
- For 2XVQ, center x = 0, center Y = 5, center Z = -24, dimension  30 x 30 
x30 and spacing of 1 Angstrom, with a total of 29791 total grid points per map. 
- For 2XBD, center x = 5, center Y = -9, center Z = -7, dimension  20 x 26 
x 30 and spacing of 1 Angstrom, with a total of 20181 total grid points per map. 
- For 2XBG, center x = -3, center Y = -15, center Z = -9, dimension  26 x 
26 x 30 and spacing of 1 Angstrom, with a total of 22599 total grid points per 
map. 
The grid box was set around the ligands binding structure to fully cover the 
entire binding site and accommodate ligands to move freely. The best pose was 
chosen with the lowest docked energy, after the docking search was completed.  
USFC Chimera (version 1.5.2 build 32411) was used to read the Autodock 
results and to obtain the images, views presented in this work, as well as the 
videos presented in the thesis defense.  
For the 2D interactions PoseviewWeb 1.97.02, [28,29] was used to 
represent all possible interactions and fully characterize them. Chain A from all 
the structures was used and the best poses for all ligands in “mol2” files 
(obtained from autodock, the pdbqt files that are those carry the binding modes 
for the ligands, we just save them with this extension and run the 2D simulation 
with the program). These kinds of extension retain all the Cartesian coordinates 
like the .pdb files, so the program known where in space is the ligand interacting 
with the protein.!
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5. ENANTIOSELECTIVE BINDING OF A LANTHANIDE (III) 
COMPLEX TO HSA STUDIED BY 1H STD NMR TECHNIQUES 
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5. Enantioselective binding of a lanthanide(III) complex to human serum 
albumin studied by 1H STD NMR techniques 
 5.1 Abstract 
The enantioselective binding of the (SSS)-! isomer of an yttrium (III) 
tetraazatriphenylene complex to ‘drug-site II’ of human serum albumin (HSA) was 
detected by the intensity differences of its STD 1H NMR spectrum relative to the 
(RRR)-" isomer, by the effect of the competitive binder to that site, N-dansyl 
sarcosine, upon the STD spectrum of each isomer, in the presence of HSA and 
by 3D docking simulations. 
 
5.2 Introduction 
 Highly emissive complexes of the lanthanide (III) ions show great promise 
as chemosensors for potential application in studying biological systems.[72-80] 
Much current research focuses on the relationship of structure to various aspects 
of chemical and biological behaviour, in order to improve promising complexes 
and to design new complexes for specific purposes.[81-86] 
In order for a lanthanide (III) complex to have potential utility as a 
biological probe, it must retain its selectivity and response in the cellular 
environment, notably in the presence of the high intracellular concentrations of 
proteins. Recent studies of potential luminescent lanthanide probes have 
investigated the effect of protein binding on their in vitro behaviour. [86-88] One 
such investigation yielded a novel example of dynamic helicity inversion following 
enantioselective protein binding: the (SSS)-! enantiomer of [Ln.L]3+ binds to 
human serum albumin (HSA) with a resulting helicity change as measured by 
circularly polarised luminescence (CPL). [88] In contrast, the (RRR)-" 
enantiomer associates more weakly with the protein and does not exhibit this 
inversion. This behaviour was unique to the complex structure, and was not 
replicated by other complexes bearing either the same chromophore or pendant 
arms. Here, we report efforts to define the regions of the complex, which bind to 
the protein by employing saturation transfer difference (STD) NMR techniques. 
STD NMR requires the use of a diamagnetic metal ion, which precludes 
the direct study of Eu(III) or Tb(III) complexes. The diamagnetic yttrium (III) is a 
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good model for Eu(III) and Tb(III), with an ionic radius that is only 0.02 Å smaller 
than Tb(III) in nine-coordinate systems. Y(III) complexes were synthesized from 
the (RRR) and (SSS) isomers of L from yttrium acetate, using analogous 
procedures to those described previously for Eu(III), Tb(III) and Gd(III) complexes 
of L.[75] 
The aim of this study was to see if STD-NMR could distinguish this 
enantiomeric pair of isomers, and map the epitope of the binding. Also a 3D 
model obtention for the interaction is aimed after competitive STD.  
  
5.3 Results and Discussion 
The full assignment for the complexes was performed (Fig. 31) to allow the 
epitope mapping. Complete analysis of gCOSY spectra (Appendix 1) was 
achieved to fulfill this demand.  
 
Figure 31. 1H NMR assignments for the (SSS)- ! [Y.L]3+ complex 
We can see that the third pendant arm is the one with the highest value for 
chemical shifts both for the phenyl and methyl resonances. This shift is 
consistent with a deshielding ring current effect associated with a through-space 
interaction involving another aromatic system. 
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Figure 32 represent the 1H NMR spectra of S-(!)-[Y.L1]3+ and RRR-(")-
[Y.L2]3+ respectively. Despite some resonances that we considered as impurities, 
both spectra are very similar.  
 
Figure 32. The 1H DPFGSE spectrum of a mixture of 500 #M of (SSS)- ! [Y.L]3+ complex (upper) 
and 500 #M RRR-(")-[Y.L1]3+ complex (lower). Trim pulse was used in both experiments to 
suppress the protein resonances.   
 
Figure 33 represents the STD NMR spectra of the two mixtures, SSS- and 
RRR-, respectively. At naked eye it is quite difficult to distinguish differences 
between the spectra, however, when both epitopes are carefully analyzed they 
show very different results. Table 1 gathers the information about peak picking 
and the determined binding epitope for the two interactions. Only two peaks have 
a difference in GEM % values below 10, those are the peaks at 8.53 ppm and at 
1.93 ppm. The percentage of saturation was determined referent to the peak at 
proton 1´(9.86 ppm), following the protocol that the highest STD amplification 
factor is set as 100%. 
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Table 1. STD amplification factor (ASTD) and relative STD (to the most shifted proton) for 900 µM 
(SSS)-! and (RRR)- " [Y.L]3+ in the presence of 30 µM HSA. 
 
Given the HSA binding isotherm for the (SSS)-! isomer (log K = 5.1 for a 
1:1 binding model) and the observed multi-site binding of the (RRR)-" isomer 
consistent with stepwise formation of various adducts of lower affinity, [88] higher 
ASTD values of the (SSS)-! isomer protons are attributed to its stronger protein 
interaction. 
 
 
 
 
 
 
Figure 33. 1H STD NMR spectrum of 1000 #M SSS-($)-[Y.L]3+ (upper) and 1000 #M RRR-(")-
[Y.L]3+ (lower) with 30 #M HSA. Trim pulse was used in both experiments to suppress the protein 
resonances. Saturation was performed at -0.5 ppm.  
The protons that appear in the standard NMR spectrum, but not in the 
STD spectrum, correspond to the cyclen ring and the amide methylene groups, 
which do not interact with the protein, consistent with their location in the centre 
Proton - 
ppm 
            (RRR)-! [Y.L]3+ 
ASTD             Relative STD (%) 
(SSS)-" [Y.L] 3+ 
    ASTD       Relative STD (%) 
% (SSS) – 
%(RRR) 
1’ – 9.6 3.51 100 4.08 100 - 
3 – 9.5 2.50 71.2 3.86 94.6 23.4 
3’ – 9.3 1.46 41.5 2.41 59.0 17.5 
2’ – 8.35 2.63 75.0 3.24 79.5 4.5 
f – 7.04 1.88 53.6 3.19 78.1 24.5 
2(e.d) – 6.4 2.48 70.8 3.75 91.8 21.1 
4.4’ – 3.2 1.65 47.1 2.67 65.4 18.2 
5.5’ – 2.0 1.74 49.6 2.86 70.0 18.5 
Me.2 – 1.6 0.62 17.6 1.03 25.2 7.6 
Me.1 – 1.1 1.34 38.2 2.07 50.8 12.5 
Me.3 – 0.8 1.21 34.6 2.11 51.7 17.1 
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of the complex, shielded by the pendant arms and chromophore. In addition, 
protons from the pendant arm that interacts with the chromophore and the 
cyclohexyl ring of the chromophore do not appear in the STD spectrum, or have 
very similar ASTD values to the (RRR)-! enantiomer, indicating that this moiety 
is not in the main core of the interaction with HSA. 
A competitive test was carried out with N-dansyl sarcosine with both 
isomers and with 30 "M HSA. Figure 34 represents the STD NMR spectra of 
SSS-(#)-[Y.L1]3+ and RRR-(!)-[Y.L2]3+ with N-Dansyl sarcosine. A few differences 
for the isomers are visible, but after the integration and analys, a more close 
competition for the binding site by SSS-(#) isomer was depicted. 
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Figure 34. 1H STD NMR spectrum of 900 "M SSS-(#)-[Y.L]3+ (upper) and 900 "M RRR-(!)-
[Y.L]3+ (lower), with 1000 "M N-Dansyl Sarcosine and 30 "M HSA. Trim pulse was used to 
suppress the protein resonances. Saturation was performed at -0.5 ppm. 
 
STD amplification factors for the (SSS)-$ isomer in the presence of N-
dansyl sarcosine are vastly different from those measured in the absence of the 
competitor, while there is less difference for the (RRR)-! enantiomer (Table 2). 
These results corroborate the findings of the relaxivity studies. [88] 
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Table 2. Change in relative STD (to the most shifted proton) for 900 mM (SSS)-! and (RRR)-
 ! [Y.L]3+ in the presence of 30 mM HSA upon addition of 2 mM N-dansyl sarcosine. 
 
 
 
 
 
 
 
 
 
 
In order to provide a 3D model for this interaction, molecular docking 
simulations with HSA binding site II with both enantiomers was performed using 
Autodock Vina. [25] This software, however, does not support Yttrium, and thus it 
was removed, remaining its structurally unchanged cage. Since, due to this 
limitation, three units of positive charge and its subsequent energy interaction are 
lost, these simulations are considered a qualitative three-dimensional search and 
not a quantitative model.  
Figure 35. A) N-dansyl sarcosine, a known a binder of HSA drug site II. Overlay of structures 
from X-ray structure 2XVQ.pdb, (red) and docked with Autodock Vina (green); B) 2D scheme for 
interactions between N-dansyl sarcosine and site II of HSA, (black dashed lines – hydrogen 
bonds; green solid lines – hydrophobic interactions) 
                 % of change after N-dansyl-sarcosine adition 
!!!!!!!!!!(RRR)-" !!!!!!!!!!!!!!!!!!!!!!!!!(SSS)-! !
- - 
8.8 -30.5 
12.0 -36.8 
23.9 24.7 
0.5 -62.8 
15.4 -37.7 
-16.5 -41.1 
-13.1 -33.8 
-4.9 -14.6 
-10.8 -30.6 
-0.5 -15.9 
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Figure 36. A and B) Docked structure for (SSS)-! isomer (cyan) overlaid with and without N-
dansyl sarcosine (red), respectively. Indicating a specific competition for this site and a lodging 
inside the binding site. C) 2D scheme for interactions between (SSS)-! isomer and site II of HSA 
(black dashed lines –hydrogen bonds, green solid lines – hydrophobic interactions; green dashed 
lines – Pi-cation interactions). 
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Figure 37. A and B) Docked structure for (RRR)-!  isomer (yelow) overlaid with and without N-
dansyl sarcosine (red), respectively. Indicating a specific competition for this site and a lodging 
inside the binding site. C) 2D scheme for interactions between (SSS)-! isomer and site II of HSA 
(black dashed lines –hydrogen bonds, green solid lines – hydrophobic interactions; green dashed 
lines – Pi-cation interactions). 
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The simulated 3D orientation of N- dansyl sarcosine at the HSA binding 
site II and the 2D interaction model coincides with the X-ray structure (Figure 35 
A,B) and validate this simulation model. 
The 3D scheme (Figure 36 A and B) shows that the (SSS)-! isomer 
interacts directly with the drug site II, mainly through the phenylmethyl pendant 
arms and the aromatic region of the chromophore, as suggested by the STD 
NMR data. This provides an explanation for the observation that this binding 
behaviour requires conservation of both the chromophore structure and the 
pendant arms. A 2D model (Figure 36 C) was also established based on the 
docking results and using Poseview which highlights the direct competition of the 
complex with N-dansyl sarcosine for interaction with the same residues, mainly 
Tyr 411, Asn 391 and Leu 387. This 2D view depicts the hydrophobic contact of 
the phenylmethyl pendant arms and the chromophore with HSA, which is further 
stabilized by an hydrogen bond between Asn 391 and a chromophore nitrogen. 
However for the (RRR)-!  isomer 3D simulation, a different interaction is 
depicted, coherently with the NMR results. The region of the cromophore is not 
lodged in the same region of N-dansyl sarcosine (Fig. 37), it seems that this 
interaction is made by the first phenylmethyl arm. Despite the fact that the  
(RRR)-!  isomer shares some similar residues of drug site II with the other 
isomer (also detected by STD-NMR), these 3D simulations support the 
preference of the protein binding site II for the (SSS)-! [Ln.L]3+ isomer.   
In conclusion, this work has demonstrated the utility of STD NMR 
experiments in providing detailed structural information about the protein binding 
interaction. The study confirms that (SSS)-! [Ln.L]3+ associates selectively with 
HSA compared to the (RRR)-" enantiomer, and identifies the regions of the 
complex which directly interact with drug site II of the protein.   
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6. Selective Contrast agents – HSA binding model characterization by 1H 
STD-NMR 
6.1 Abstract 
STD NMR was used to study the HSA interaction of three MRI contrast 
agents and the KD for this interaction with HSA was found for all complexes using 
the initial slopes protocol. La(BOPTA) and La(DTPA-Cholate) interact mainly with 
HSA´s drug site I while La(NAPHTO) does not posses a specificity for both drug 
sites. La(DTPA-Cholate) was found to have a lower KD than all the other CA´s 
and the 3D docking simulation model built with X-ray structures of HSA supports 
all STD NMR findings. The protocol of STD and competitive STD followed by 
docking simulations was found to be a robust tool to characterize protein-ligand 
interactions. 
 
6.2 Introduction 
 It is now well established that the information content of a magnetic 
resonance imaging (MRI) experiment can be significantly enhanced by the use of 
a suitable contrast agent (CA). Nowadays about 35% of MRI scans make use of 
CAs and it is expected that this percentage will further increase with the 
availability of more sensitive and specific agents. [89–92] A MRI CA is not directly 
visualized in the image, only its effects on water proton relaxation times are 
observed. The increased relaxation rates allow the attainment of an intense 
signal in a short time and a better signal-to- noise ratio by the acquisition of a 
higher number of measurements. 
As unpaired electrons display a remarkable ability to reduce T1 and T2, the 
search for efficient CAs has focused on paramagnetic metal complexes. The 
metal of choice has been the GdIII ion due to its high paramagnetism (seven un- 
paired electrons) and for its favourable properties in terms of electronic 
relaxation.[93] This ion forms very stable complexes with polyamminocarboxylate 
ligands and Gd-DTPA (Magnevist) was the first MRI CA approved for clinical use. 
Since then, other GdIII-based CAs similar to Magnevist has been introduced into 
clinical practice. They have very similar pharmacokinetic properties because they 
are distributed in the extracellular fluid and are eliminated via glomerular filtration. 
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The relative ability of a paramagnetic metal complex to act as a MRI CA is 
expressed by its relaxivity, that is, the property that is a measure of the relaxation 
enhancement of water protons in solution containing the paramagnetic agent at a 
1 mm concentration. [94] Much work has been carried out in the last two decades 
to improve the relaxivity of GdIII-based agents. It was recognised early on that 
high relaxivities could be attained for slow-moving systems endowed with fast 
exchange rates of the coordinated water molecule(s) and suitably long electronic 
relaxation rates of the unpaired electrons on the metal ion. [91,92,95] On this 
basis several macromolecular systems have been designed in which the GdIII 
chelates are either covalently or non-covalently bound to high molecular weight 
substrates. In particular much attention has been devoted to supramolecular 
adducts formed by suitably functionalised GdIII chelates and human serum 
albumin (HSA). Due to their increased retention in the vascular system, these 
CAs can also be used for 3D imaging of the vasculation in MRA.  [95] 
In this study three selective contrast agents were studied on their 
interaction with the main blood carrier HSA, Gd(BOPTA), Gd(DTPA-Cholate) and 
Gd(NAPHTO-EGTA), using their diamagnetic La(III) analogues.  The contrast 
agents used in this are categorized as contrast agents to magnetic resonance 
angiography (MRA), and therefore they should probably be carried by HSA. 
There is the exception on La(BOPA) (MultiHance® from Bracco Diagnostics, 
Inc.) that is indicated by FDA for intravenous use in magnetic resonance imaging 
(MRI) of the CNS in adults to visualize lesions with abnormal blood brain barrier 
or abnormal vascularity of the brain, spine, and associated tissues that can be 
used for MRA but also for increase contrast in brain tissues and liver. 
Direct competitive studies were performed with known inhibitors of albumin 
binding site I such as Warfarin, and binding site II such as Ibuprofen and L-
Tryptophan. This direct competition was used primarily to disclose the binding 
site of the contrast agent in the HSA protein and with this ligand-protein complex 
establish the ligand epitope .In order to calculate a good affinity constant 
approximation and the mode of binding a recent protocol was followed. [33]  
A comprehensive and valid model for the interaction was established with 
docking, for all the studied interactions after having all the quantitative results 
from NMR. 
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6.3 RESULTS AND DISCUSSION  
6.3.1 La(BOPTA) 
! Comparing the 1H Wsupp and the STD NMR spectra of a mixture of 
La(BOPTA) and HSA, are seen in the STD spectrum, almost only those 
resonances from the aromatic ring, the anchor moiety of the contrast agent. 
Those resonances near 4.6-4.8 ppm are not visible in the reference spectrum, 
once they were saturated in the DPFGSE suppression scheme; therefore it is not 
possible to characterize their degree of saturation in the STD NMR spectrum. 
However, despite their almost negligible intensity, there are also other 
resonances from the complex cage present in the STD NMR spectrum.!
The aromatic resonances of La(BOPTA) were here treated as a whole due 
to the fact that they are overlapped. The STD amplification factor (ASTD) found for 
a mixture of 1 mM of La(BOPTA) and 30 !M of HSA (Fig. 38) was 5.04. After the 
analysis of the STD NMR spectrum of this reference the assays of direct 
competition were aligned. No GEM was performed due to the fact that only a 
resonance became visible in the STD NMR spectrum. 
 
 
 
 
 
 
 
 
 
 
 
 
!
Figure 38. (A) The 1H DPFGSE spectrum of a mixture of 1 mM La(BOPTA), and 30 !M HSA (B) 
The STD NMR spectrum of the same mixture. Trim pulse was used in both experiments to 
suppress the protein resonances. 
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! Analysing the 1H Wsupp reference spectrum and the corresponding 1H 
STD NMR spectrum of a mixture of 1 mM of La(BOPTA), 640 !M of Ibuprofen 
and 30 !M of HSA (Fig. 39) the ASTD of the aromatic signal calculated to be 0.87, 
and thus it suffered a 83% reduction (since the conditions of the CA and the HSA 
were maintained, the reduction of the ASTD can only be justified by a direct 
competition for  Ibuprofen’s binding site). 
!
Figure 39. (A) The 1H DPFGSE spectrum of a mixture of La(BOPTA), 1 mM, Ibuprofen 640 !M 
and HSA, 30 !M (B) The STD NMR spectrum of the same mixture. Trim pulse was used in both 
experiments to suppress the protein resonances. 
 
 In an analogous way the 1H Wsupp reference and STD NMR spectra of a 
mixture of 1 mM of La(BOPTA), 0.2 mM of Warfarin and 30 !M of HSA (Fig. 40) 
were used to calculate the ASTD of 0.11 resulting of the competition of Warfarin 
for interaction between the CA and the protein, which means that the presence of 
the La(BOPTA) resonances in the STD NMR spectrum practically disappeared. 
In this competition experiment, the obtained ASTD for the aromatic moiety of 
La(BOPTA) suffered a 99% decrease relative to the  ASTD reference value (Table 
3).  
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In this competition experiment the ASTD obtained along with the observable 
STD response of the La(BOPTA) in the presence of Warfarin give us an accurate 
result, and it is correct to assume that the binding of La(BOPTA) happens mainly 
through the site I of Human Serum Albumin. A competitive experiment between 1 
mM of La(BOPTA) and 50 !M of Warfarin in the presence of 30 !M of HSA 
output a ASTD of 1.31. Although some overlap with the Warfarin resonances is 
considered, the resonances of the aromatic region of La(BOPTA), despite  their 
lower intensity, are visible. 
A control test using a mixture of Warfarin and L-Tryptophan was 
performed to attest that Warfarin did not displaces the L-Tryptophan from the 
STD NMR spectra, which is consistent with the information from literature [21]. It 
is well known that L-Tryptophan binds to the site II of HAS, while Warfarin binds 
to site I. Therefore, no direct competition was expected. Moreover, this data 
corroborates the data obtained in the competition of La(BOPTA) and Warfarin. 
 Thus we performed a competitive test between La(BOPTA) and L-
Tryptophan (Fig. 41). The ASTD found in these conditions was 3.62, showing a 
decrease of about 29% relative to the ASTD value of La(BOPTA) with HAS (see 
Table 5). 
 
 
  
Figure 40. (A) The 1H DPFGSE spectrum of a mixture of La(BOPTA), 1 mM, Warfarin 200 !M and 
HSA, 30 !M (B) The STD NMR spectrum of the same mixture. Trim pulse was used in both 
experiments to suppress the protein resonances.  
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La(BOPTA) ASTD Aromatic ppm 
ASTD % 
reduction 
Free 1 mM 5.04 0 
 
Ibuprofen 640 !M 0.87 83 
 
Warfarin 200 !M 0.11 99 
L-Tryptophan 1000 !M 3.62 
 
29 
 
 
The data analysis of the observable STD response of the La(BOPTA) in 
the presence of Warfarin gives proof that the binding of La(BOPTA) happens 
mainly through the site I of HSA. 
It is known from literature that Ibuprofen binds to site 2 of HSA with a 
dissociation constant of 0.37 !M. [21] On the other hand, a looser interaction is 
expected for La(BOPTA), with values of KD between 5 mM and 0.17 mM 
(unpublished results). However, it has also been reported that Ibuprofen is able 
to displace ligands that bind to site I (Warfarin) of HSA, although with a lower 
affinity constant. If the displacement registered in the Ibuprofen competitive 
Figure 41. (A) The 1H DPFGSE spectrum of a mixture of La(BOPTA), 1 mM, L-Tryptophan, 1 
mM, and HSA, 30 !M (B) The STD NMR spectrum of the same mixture. Trim pulse was used in 
both experiments to suppress the protein resonances$!
!
Table 3. Data treatment for the competitive STD assays performed for La(BOPTA) and HSA. 
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assays was due to a direct competition for the binding site II of HSA, we would 
expect a higher intensity of the La(BOPTA) signal in the STD NMR spectra 
correspondent to the competition with the Warfarin. Therefore, taking to 
consideration the amount to Ibuprofen present in the competitive experiment and 
the binding constants from literature, we conclude that the displacement of 
La(BOPTA) by Ibuprofen is mainly due to a interaction of Ibuprofen with the site I 
of HSA, either by direct competition of by an allosteric effect. 
After this conclusion, was established a one-site binding model for this 
interaction and calculated the corresponding dissociation constant using STD 
titration with six different La(BOPTA) concentrations and an array of five 
saturation times. The data treatment was performed according to the protocol of 
the Binding Isotherm of STD Initial Growth Rates, described by Angulo, et al. [33] 
(Fig. 42). The saturation rate and maximum STD values are shown in Table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LA(BOPTA) uM 250 400 500 700 900 3000 
ASTD -max 2.5 3.68 4.99 4.87 6.98 8.65 
Ksat 0.77 0.75 0.87 0.71 0.81 0.93 
Initial Slope 3.24 4.92 5.74 6.87 7.64 9.3 
!
Figure 42. Plot of different concentrations of LA(BOPTA) with, 0,5, 1, 2, 3 and 5s of saturation 
time of 30uM of HSA with the equation STD-AF=STD-AFmax[1-exp(-ksat*tsat) .!
!
!
Table 4. Saturation rate,  Ksat, and the maximum ASTD value (ASTD-max) for La(BOPTA).!
!
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! After plotting the initial slopes into a one-site binding model (Fig. 43) the 
KD value of 483 !M was obtained with a R2 of 0.96 and error margin of 14%. This 
good result is in agreement with the expected value from other techniques 
(unpublished results by Aime et al), and it places this new protocol as 
advantageous to obtain a correct KD estimation, when compared with a simple 
ligand titration plot with a given saturation time. The protocol requires five times 
longer but yields a value about 30% more accurate (for this 483 !M the old 
protocol gives a 700 !M KD value). 
!
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! !
 
 
 
 
 
 
 
 
 
 
The quantitative approach obtained by STD NMR was qualitatively 
represented in a simulated 3D model using Autodock Vina. [25] The structure 
used for establishing this model was the X-ray structure of HSA complexed with 
Warfarin, a HSA´s widely known binder for drug site I. With this structure the 
dynamics of that binding pocket is maintained and the approximate calculation for 
the CA becomes more closely related to what happen in a real interaction. 
To validate the model a simulation was made to see if the program 
calculated the correct 3D orientation for Warfarin, Figure 44A. The results 
support the previous conclusions and allow us to establish a coherent model for 
the binding site I. When the 3D data for La(BOPTA) was completed it was clear 
Figure 43. Plot of different concentration of LA(BOPTA) with the one site binding model 
equation – Y=Bmax*X/(KD+X). Bmax of 10.77 +- 0.8 and a KD of 483+- 72.83 !M with a R2 of 
0.96. 
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that it was in adjust with the STD NMR data and that the compound was in a 
direct competition for HSA´s drug site I, mainly through the aromatic moiety of the 
CA (Fig. 44 C and D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. A) Overlay of the representations of Warfarin and BOPTA. In red  and purple are, 
respectively, the warfarin in X-ray structure 2BXD and the simulated one,using Autodock Vina. 
Depicting almost co-orientation of warfarin and a direct competition by BOPTA. B and C) 2D 
Interactions between warfarin and BOPTA, with site I of HSA, respectively. 2D calculation were 
obtained with Poseview Software; black dashed lines – hydrogen bonds; green solid lines – 
hydrophobic interactions; green dashed lines – Pi-Pi or Pi-cathion interactions; 
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The main residues involved in this interaction are quite similar for Warfarin 
and La(BOPTA), indicating direct competition. A huge set of hydrophobic 
interactions and a pi-pi stacking between the BOPTA aromatic moiety and Trp 
214, support the high ASTD values for this moiety when compared with the 
remaining portion of the CA.  
In summary, it is clear that the La(BOPTA) interaction with HSA occurs at 
drug site I and that the full characterization of this interaction can be made by 
STD NMR. An accurate KD for the interaction was calculated and docking 
simulations depicted the HSA´s residues involved, with all the results in perfect 
agreement. 
 
6.3.2 La (DTPA-Cholate)  
  
Following the same protocol, the La(DTPA-Cholate) compound was 
studied by STD NMR. Figure 45 represents the 1H Wsupp and the STD NMR 
spectra of a mixture of 500 !M La(DTPA-Cholate), and 30 !M HSA. The STD 
NMR spectrum shows that almost all the resonances from the Cholate moiety are 
present, of which those that rise the more intense in the spectrum are the sharp 
resonances at 0.995 and 0.985 (due to their overlapping these resonances were 
treated as a single one) and 0.751 ppm. This result is concordant with the 
expectations since most of the anchor group should fit in the binding pocket. The 
resonances from the reporter group are not visible in the STD NMR spectrum, as 
in this case, the size of the binding moiety places the chelate group far from the 
protein surface. Since the sharp resonances from the methyl groups below 1 ppm 
are the more visible in the whole set of experiments we choose them to evaluate 
the competition assays that follows. Therefore, the ASTD for this interaction was 
determined to be 0.85 for the peak at 0.99 ppm and 0.91 for the peak at 0.751 
ppm, having this reference for the competitive studies. 
Although the “OH” protons resonance (see annex 1), around 4 ppm, 
appear to also interact they have relatively smaller values for ASTD to the methyl 
values and the group epitope mapping was not performed due to the massive 
overlap in Cholate moiety NMR signals. 
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Three competitive STD experiments between La(DTPA-Cholate) and 
Ibuprofen were performed. The results, depicted in Figures 46 and 47 correspond 
to concentrations of Ibuprofen of 500 !M, 700 !M. For these competitions the 
obtained ASTD values were, 0.32, and 0.33, a 65 and 66 % decrease of ASTD value 
respectively. From the analysis of the STD NMR spectrum (Table 5 and Fig. 47), 
it is correct to say that with an increase of 200 !M in the Ibuprofen concentration 
no significant effect was manifested. Some overlapping with the base of the 
Ibuprofen signal closer to 1ppm might increase the ASTD obtained for this 
interaction. Since the La(DTPA--Cholate) has resonances at the very low ppm 
region of the spectrum the selective saturation pulse was applied at the aromatic 
region of the protein, thus interacting with the Ibuprofen resonances. This might 
be the reason why the Ibuprofen signals appear so intensely in the STD NMR 
spectrum. At very high concentration of Ibuprofen the signal from the CA is 
almost null, only residual resonances are visible. 
 
 
 
 
 
Figure 45. (A) The 1H DPFGSE spectrum of a mixture of 500 !M La(DTPA-Cholate), 0.5 mM, 
and HSA, 30 !M (B) The STD NMR spectrum of the same mixture. Trim pulse was used in both 
experiments to suppress the protein resonances. 
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Warfarin experiments showed a greater displacement of the La(DPTA-
Cholate) binding, Figures 48 and 49. The ASTD for two competitive experiments 
for 500 !M and 100 !M Warfarin were determined to be 0.18 and 0.19, 
respectively. The averaged 81% decrease of ASTD   results show that Warfarin 
displaces effectively the CA at lower concentrations.   
Figure 46. (A) The 1H DPFGSE spectrum of a mixture of La(DTPA-Cholate), 500 !M, 
Ibuprofen 500 !M and HSA, 30 !M (B) The STD NMR spectrum of the same mixture. 
Trim pulse was used in both experiments to suppress the protein resonances. 
!
Figure 47. (A) The 1H DPFGSE spectrum of a mixture of La(DTPA-Cholate), 500 !M, 
Ibuprofen 700 !M and HSA, 30 !M (B) The STD NMR spectrum of the same mixture. Trim 
pulse was used in both experiments to suppress the protein resonances. 
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From the competitive STD assay between the CA in study and L-
Tryptophan, Figure 50, was obtained an ASTD of 0.92, and as expected only a 8% 
attenuation of signal intensity, which means that there virtually no displacement 
in the presence of L-Tryptophan, nor the L-Tryptophan was significantly 
displaced.  
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Figure 49. (A) The 1H DPFGSE spectrum of a mixture of La(DTPA-Cholate), 500 !M, 
Warfarin 500 !M and HSA, 30 !M (B) The STD NMR spectrum of the same mixture. Trim 
pulse was used in both experiments to suppress the protein resonances. 
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Figure 50. (A) The 1H DPFGSE spectrum of a mixture of La(DTPA-Cholate), 500 !M, L-
Tryptophan 500 !M and HSA, 30 !M (B) The STD NMR spectrum of the same mixture. Trim 
pulse was used in both experiments to suppress the protein resonances. 
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Since the La(DTPA-Cholate) has resonances at very low ppm region of 
the spectrum the selective saturation pulse was applied at the aromatic region of 
the protein, thus interacting with the Ibuprofen resonances. This is the reason 
why the Ibuprofen resonances appear so intensely in the STD NMR spectrum. At 
very high concentration of Ibuprofen the signal from the CA is almost null, only 
residual resonances are visible. 
La(DTPA-Cholate) 500 !M      ASTD  ASTD reduction (%) 
Free 500 !M 0.91 0 
Ibuprofen 500 !M 0.32 65 
Ibuprofen 700 !M 0.33 66 
Warfarin 100 !M 0.19 80 
Warfarin 500 !M 0.18 81 
L-Typtophan 500 !M 0.93 -2 
"#$%&!'(!$%&%!&'(%&)(*&!+,'!&-(!.,)/(&0&01(!23$!%44%54!/('+,')(6!+,'!7%8$39:;<-,=%&(>!+,'!&-(!!
?@AB!//)!40C*%=@!
!!
!
"#!
The Warfarin experiments showed a larger displacement of the La(DPTA-
Cholate) binding and so we conclude that the binding of this complex occurs at 
the site I (Warfarin) of HSA. We argue that if the binding of La(DTPA-Cholate) 
would occur at the site II (Ibuprofen) a significant displacement of the L-
Tryptophan should be observed. 
To calculate the dissociation constant was used once again the Binding 
Isotherm of STD Initial Growth Rates protocol. [33] The peak chosen was the one 
with high ASTD value, at 0.75 ppm. Concentrations that best fitted the model are 
plotted against saturation time in Figure 51 and the saturation rate and maximum 
STD values are shown in Table 6. These values were used for KD estimation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
La(DTPA-Cholate) !M 60 200 300 600 700 900 
ASTD -max 0.65 0.75 0.79 0.86 0.88 0.92 
Ksat 0.94 0.78 0.78 0.84 0.84 0.83 
Initial slope 0.69 0.96 1.01 1.02 1.05 1.11 
  
 The initial slopes were plotted into a one-site binding model (Fig. 52) and a 
KD of 36 !M was obtained with a R2 of 0.98 and error margin of 11%. This result is 
in agreement with the expected value obtained from other techniques, which was 
around 20 !M (unpublished results by Aime et al). As we can see, acquiring 
Figure 51. Plot of different concentrations of LA(DTPA-Cholate) with, 0,5, 1, 2, 3 and 5s of 
saturation time of 30 !M of HSA with the equation STD-AF=STD-AFmax[1-exp(-ksat*tsat) .!
!
!
Table 6. Saturation rate,  Ksat, and the maximum ASTD value (ASTD-max) for La(DTPA-Cholate) 
for the 0.75 ppm signal.!
!
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some more points on the ascendant portion of the curve, between 60 and 200 !M 
should improve the result and decrease a little bit more the KD values, 
nevertheless the protocol for this parameter is quite successful. 
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The quantitative approach obtained by STD NMR was three-dimensionally  
simulated for HSA´s binding site I 3D model. The supported model was able to 
establish a very clear interaction between the CA and the binding site. STD NMR 
revealed a variety of relative small and overlaid resonances appearing on the 
spectra, and now its safe to assume that this effect is due to the embded position 
for DTPA-cholate in the biding site. The CA into binding site I through its Cholate 
moiety, explaining also such a low dissociation constant. (Fig. 53) 
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Figure 52. Plot of different concentration of LA(DTPA-Cholate) with the one site binding 
model equation – Y=Bmax*X/(KD+X). Bmax of 1.117 +- 0.001 and a KD of 36 +- 3.99 !M with a 
R2 of 0.98. 
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Figure 53. Overlay of the representations of Warfarin (green) and DTPA-Cholate  (red) and HSA 
(cornflower blue). Depicting a direct competition for the binding site.  
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
Figure 54. 2D scheme with interactions between DTPA-cholate with site I of HSA. 2D calculation 
were obtained with Poseview Software (black dashed lines – hydrogen bonds; green solid lines – 
hydrophobic interactions). 
!
The main residues involved in this large interaction is those already known 
for this binding site. Analysing Figure 54, a large set of hydrophobic interactions 
and some hydrogen bounds stabilize the CA-protein interaction, this interaction 
being also responsible for the good affinity between the studied system.  
In summary, it can be concluded that the La(DTPA-Cholate) interaction 
with HSA occurs via drug site I and the full characterization of this interaction was 
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made by STD NMR. An accurate KD value for the interaction was calculated and 
docking simulations depicted the HSA´s residues involved.  
 
6.3.2 La (NAPHTO-EGTA) !
 
The HSA-CA binding studies follow with La(NAPHTO-EGTA) (Fig. 55) 
shows the 1H Wsupp spectrum and the STD NMR spectrum of this compound at 
500 !M in the presence of 30 !M of HSA. Only the resonances from the 
naphtalene group are present in the STD NMR spectrum. Moreover, it is clear 
that the relative intensities between these peaks differ from the 1H to the STD 
spectrum. The intensity of the singlet at 7.54 ppm is much lower in the STD than 
in the 1H spectrum, as this singlet corresponds to the two protons of the naftalene 
that are closest to the chelating group of the molecule (see Annex I for full 
assignment). 
The ASTD for this interaction was 1.45 for the peak at the highest ppm 
value (Table 7). Due to the overlapping of the other proton peaks, and to the fact 
that it presents 70 % of saturation transfer relative to the high ASTD value for the 
most shifted resonance, this signal was easily picked to follow competition 
studies and KD estimation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55. (A) The 1H DPFGSE spectrum of a mixture of 500 !M La(NAPTHO-EGTA), and HSA, 
30 !M (B) The STD NMR spectrum of the same mixture. Trim pulse was used in both 
experiments to suppress the protein resonances. 
  The competitive assay between an equimolar mixture of La(NAPHTO -
EGTA) and 500 !M Ibuprofen with 30 !M HSA  shows no reduction of the peak 
intensities in the STD NMR spectrum for the La(NAPHTO-EGTA) – Figure 56.  
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A similar assay of 30 !M HSA with an equimolar mixture of the CA and 
Warfarin at 500 !M was performed. Again, no reduction in the signals from 
La(NAPHTO -EGTA) is observed (Fig. 57).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57.(A) The 1H DPFGSE spectrum of a mixture of 500 !M La(NAPHTO -EGTA), 500 !M 
Warfarin and 30 !M HSA. (B) The STD NMR spectrum of the same mixture. Trim pulse was used 
in both experiments to suppress the protein resonances. 
 
Then a competitive test with L-Tryptophan at 500 !M and 30 !M HSA was 
performed. Here, both L-Tryptophan and La(NAPHTO-EGTA) were present in the 
STD NMR spectrum with intensities similar to the control test. Moreover, a 
resonance from the chelate group at 3.8 ppm appears in the STD NMR spectrum 
(Fig. 58).  
!
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Figure 56. (A) The 1H DPFGSE spectrum of a mixture of 500 !M La(NAPHTO -EGTA), 500 !M 
Ibuprofen and 30 !M HSA (B) The STD NMR spectrum of the same mixture. Trim pulse was used 
in both experiments to suppress the protein resonances. 
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Figure 58. (A) The 1H DPFGSE spectrum of a mixture of 500 !M La(NAPHTO -EGTA), 500 !M 
L-Tryptophan and 30 !M HSA. (B) The STD NMR spectrum of the same mixture. Trim pulse was 
used in both experiments to suppress the protein resonances. 
 
As control test a competitive experiment between 500 !M L-Tryptophan 
and 460 !M Ibuprofen in the presence of HSA 30 !M was performed (Fig. 59). 
As expected, in the presence of Ibuprofen, the resonances from L-Tryptophan 
are not present in the STD NMR spectrum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a final experiment, containing a mixture of 500 !M of La(NAPHTO 
EGTA) and L-Tryptophan in the presence of 460 !M of Ibuprofen and 30 !M of 
HSA (Fig. 60), curiously, the resonances from L-Tryptophan appear in the STD 
NMR spectrum, although with reduced intensity. 
Figure 59. (A) The 1H DPFGSE spectrum of a mixture of 500 !M L-Tryptophan and 460 !M 
Ibuprofen and 30 !M HSA (B) The STD NMR spectrum of the same mixture. Trim pulse was 
used in both experiments to suppress the protein resonances. 
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Figure 60. (A) The 1H DPFGSE spectrum of a mixture of 500 !M La(NAPHTO.EGTA), 500 !M L-
Tryptophan and 460 !M of Ibuprofen and HSA, 30 !M (B) The STD NMR spectrum of the same 
mixture. (C) Magnification of STD NMR spectrum from7 to 8.1 ppm, depicting L-Tryptophan 
resonances. Trim pulse was used in both experiments to suppress the protein resonances 
 
!
!
!
!
!
!
!
Considering the results from the competitive assays, where ASTD increase 
after competition (Table 7), we might be in the presence of non-common binding 
characteristics. Since La(Nafto-EGTA) was not displaced neither by Ibuprofen 
nor Warfarin and since it favored the binding of L-Tryptophan we might say that 
La(Nafto-EGTA) may bind to a different site of Human Serum Albumin, a site that 
is neither site I nor II. 
To calculate the dissociation constant with the Isotherm of STD Initial 
Growth Rates protocol the peak chosen was the one with high ASTD value. 
Although competitive STD show that we are in the presence of a non-competitive 
binding CA, values fit the one-site binding model. According to Angulo et al 
La(NAFTO EGTA)  !M ASTD ASTD increase  (%) 
Free 500  !M 1.45  
Ibuprofen 500 !M 1.59 110 
Warfarin 500 !M 1.9 131 
L-Typtophan 500 !M 4.99 344 
Table 7. Data treatment for the competitive STD assays performed for La(NAPHTO -EGTA) 
most shifted resonance. 
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protocol, [33] different concentrations were plotted against saturation time in 
Figure 61 and the saturation rate and maximum STD values for the protocol are 
shown in Table 8. 
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La(NAPHTO-EGTA) !M 500 600 700 1000 1300 1500 2250 
ASTD-max 3.55 3.05 3.51 3.95 4.64 4.87 5.89 
Ksat 1.18 0.93 0.87 0.81 0.85 0.88 0.9 
Initial slope 3.02 3.31 4.04 4.86 5.47 5.56 6.55 
!
 The initial slopes were plotted into a one-site binding model (Fig. 62) and a 
KD of 1047 !M was obtained with a R2 of 0.98 and error margin of 12%. This high 
value is in agreement with a non-specific binding, that represents lower affinity 
interaction with HSA. As we have plenty of points on the ascendant portion, we 
are confident of this result. Although a non-specific binding could occur to 
another unkown site, the results seem to point this way. 
 
 
Figure 61. Plot of different concentrations of LA(NAPHTO-EGTA) with, 0,5, 1, 2, 3 and 5s of 
saturation time of 30 !M of HSA with the equation STD-AF=STD-AFmax[1-exp(-ksat*tsat) .!
!
!
Table 8. Saturation rate,  Ksat, and the maximum ASTD value (ASTD-max) for La(NAPHTO-
EGTA) for the 7.9 ppm signal.!
!
La(NAPHTO-EGTA) 
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To corroborate data obtained by STD NMR, both HSA binding sites were 
three-dimensionally simulated. The model for HSA binding site II was made with 
HSA´s X-ray structure complexed with Ibuprofen. The simulation, presented in 
Figure 63 C and D, was not as accurate as the one calculated for drug site I, 
because the overlay of deposited and calculated structures are not equivalent. 
Nevertheless, its considered a possible model for this site, once Ibuprofen is 
relatively close to the X-ray position.  
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Figure 62. Plot of different concentration of LA(DTPA-Cholate) with the one site binding 
model equation – Y=Bmax*X/(KD+X). Bmax of 9.65 +- 0.51 and a KD of 1047 +- 118.1 !M with a 
R2 of 0.98. 
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Figure 63. A and B) Overlay of the representations of Warfarin (red) and NAPHTO-EGTA (green) 
and the molecular surface of  the CA (shaded green) depicting no direct competition for drugsite I 
of HSA. C and D) Overlay of the representations of Ibuprofen from the X-ray structure (red), 
Ibuprofen simulated (purple) and NAPHTO-EGTA (green) and the molecular surface of  the CA 
(shaded green) depicting no direct competition for drugsite II of HSA. E and F) 2D scheme with 
interactions between DTPA-cholate with site I and drug site II of HSA, respectivelly. 2D 
calculation were obtained with Poseview Software (black dashed lines – hydrogen bonds; green 
solid lines – hydrophobic interactions). 
!
The main forces involved in this interaction are mainly hydrophobic 
interactions and some hydrogen bonds, but its seen that the NAPHTO moiety of 
the CA can be docked to the surface of the protein, but with no effective overlap 
with the drug portion was observed. This finding supports STD NMR results and 
$! %!
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one can conclude that no direct competition for the main drug sites of HSA is 
observed for this CA.  
Considering the affinity constant, and according to the results from the 
competitive assays, we might be in presence of non-common binding 
characteristics. Since La(NAPHTO -EGTA) was not displaced neither by 
Ibuprofen nor Warfarin and since it favoured the binding of L-Tryptophan, we 
might say that La(NAPHTO -EGTA) binds to a different site of Human Serum 
Albumin, that is neither site I nor II. The La(NAPHTO-EGTA) interaction with HSA 
occurs, as the NAPHTO moiety is prone to establish hydrophobic interactions at 
HSA´s molecular surface. The combined results point to a new, or at least 
different, but specific binding site. 
 
 
 
 
!
!
!
!
!
!
!
!
!
! !
!!
!
"#!
!
!
 
 
 
 
 
 
 
 
7. STUDY OF THE INTERACTION OF INSULIN MIMETIC 
VO(DMPP) WITH HSA BY 1H STD NMR TECHNIQUES!
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7. STUDY OF THE INTERACTION OF INSULIN MIMETIC VO(DMPP) WITH 
HSA BY 1H STD-NMR TECHNIQUES 
 7.1 Abstract 
Insulin mimetic VO(DMPP) complexes preferred binding to ‘drug-site I’ of 
HSA was detected by STD 1H NMR by the displacement effect of the competitive 
binder to that site, warfarin. The H5 proton of the free ligand was identified as the 
most interacting proton, and with higher saturation transfer than any other 
species found in solution. A 3D model simulation for this interaction was 
established using Autodock Vina.  
 
7.2 Introduction 
 In the last years Vanadium Compounds have attracted much interest due 
to their demonstrated pharmacological properties [96].  In particular, their 
potential use as oral insulin mimetics has been demonstrated by in vivo [97,98] 
and ex vivo studies [99], as well as in clinical trials [100].  
Thus, intensive research has been carried out to develop Vanadium 
Compounds to be used as orally administered drugs in the treatment of Diabetes 
Mellitus (DM), at an effective non toxic dose. Among many synthesized 
compounds, at the moment, only a few seem to be most promising, and have 
demonstrated antidiabetic properties [101-102] through indicators of insulin 
mimetism assessed through in vitro and ex vivo studies such as glucose uptake 
rates [103,104], inhibition of free fatty acid (FFA) release  [105] and specific 
protein phosphorylation [100,102]. In vivo experiments have confirmed their 
therapeutic activity and low toxicity [106,107], bioavailability and 
pharmacokinetics and established the minimum effective dose  [108].  
 In our group the, vanadium complex containing a pyridinone ligand, the 
bis(1,2-dimethyl-3-hydroxy-4-pyridinonate)oxovanadium (IV), VIVO(DMPP)2 (FIg. 
3), has been extensively studied. Its structure in the solid state was already 
determined [109], the different species which are formed in aqueous solution 
under aerobic conditions were identified using different techniques, and the 
respective formation constants were determined [110]. In vitro studies with two 
cell lines, the mice fibroblast SV 3T3 and the human skin fibroblast F26 [111] 
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were conducted. A human fibroblast cell line, 3T3-L1 [107], as well as ex vivo 
studies with human erythrocytes [112] were also carried out to test its 
cytotoxicity, and glucose uptake enhancement capacity. Recently its anti-diabetic 
action was recognized through an ex vivo study with isolated primary rat 
adipocytes, which demonstrated that this compound improves glucose 
internalization, inhibition of free fatty acids (FFA) release, and has the capacity to 
phosphorylate specific proteins of the insulin signalling cascade [113]. In vivo 
studies with obese Zucker rats, using Magnetic Resonance Techniques 
(MRI/MRS), have confirmed the positive effects of VIVO(DMPP)2 on glucose and 
lipid metabolism, reinforcing its promising anti-diabetic capacity (data to be 
published in a near future). 
 However, in spite of all these studies, the mechanism of action of 
Vanadium Compounds is not yet clarified. A main concern in this field is how the 
Vanadium Compounds are transported in the blood stream and taken up by the 
cells. It’s important to know the interactions between the administered Vanadium 
Compounds and endogenous small and/or macromolecules present in serum 
and to find out if decomposition of the external Vanadium Compounds occurs or 
a ternary complex will be formed, as well as to investigate what is the role of 
serum proteins in the transport of Vanadium Compounds [114-118]. This 
information is crucial to search for a better drug design to improve the therapeutic 
efficacy of these compounds.  
 This work reports a study of the interaction in aqueous solution of 
vandate/HDMPP complexes with human serum albumin (HSA) using the 1H NMR 
spectroscopic technique Saturation Transfer Difference (STD) [17-19], which 
provides powerful data about kinetics and binding sites of ligands to a protein, 
validation of binding epitopes, and estimation of affinity constants.  
The vanadate/HDMPP (M/L=1/2) solution contains the 1:1 and 1:2 V(V) 
species, the same which result from the dissolution of the solid V(IV)O(DMPP)2 in 
water, under aerobic conditions, as already demonstrated [110]. The use of the 
vanadate/HDMPP system instead of a aerobic solution of V(IV)O(DMPP)2  avoids 
the presence of a small amount of paramagnetic species [21], which would not 
allow the correct use of the 1H NMR spectroscopy and STD technique.  
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Competitive assays with two known inhibitors of site I and site II of HSA, 
warfarin and ibuprofen, respectively, were performed primarily to identify the 
binding sites of the compound.   
 
7.3 Results and Discussion 
The spectrum of the free ligand shows the signals corresponding to the 
two methyl groups and to the aromatic protons H5 and H6. In the spectrum 
obtained from the vanadate /DMPP solution (1:2) multiple signals for each type of 
protons are observed, indicating the presence of 3 species in solution, in slow 
exchange in the NMR time scale: the free ligand, the 1:1 VO2(DMPP)(H2O)(OH) 
and the 1:2 VO2(DMPP)2 V(V) species, assigned in the Figure 64.  
When HSA was added to the vanadate /DMPP (1:2) system, the 
resonances of the ligand in the three species broaden, as expected due to 
protein binding and the increase in solution viscosity. From STD spectra, group 
epitope mapping for the free ligand (Table 9) revealed to be the main interacting 
proton the H5 to all species, the N-CH3 and CH3 resonances had lower values. 
For the vanadate /DMPP (1:2) system only H6 and H5 were mapped due to 
overlap of the other two resonances (Table 10). 
 
Table 9. Group epitope mapping (GEM), as percentage, for the proton signals of HDMPP 
normalized relative to H5. 
 
GEM % H6 H5 N-CH3 CH3 
Free 
HDMPP 88 100 59 73 
 
Table 10. Values of group epitope mapping (GEM), as percentage, for the proton signals of 
HDMPP free, VO2(DMPP) (H2O)(OH) and VO2(DMPP)2 species, normalized relative to free 
HDMPP proton H5. 
 
HDMPP - species      ASTD GEM (%) 
H6 - 1:2 and 1:1 23.98 75 
H6 - Free 20.85 65 
H5 - 1:2 26.58 83 
H5 - 1:1 26.26 82 
H5 - Free 31.97 100 
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Figure 64. A and B) Overlay of the representations of Warfarin (red) and NAPHTO-EGTA (green) 
and the molecular surface of  the CA (shaded green) depicting no direct competition for drugsite I 
of HSA. 
Analysis of the STD spectrum and determination of GEM values indicate 
that there is a preference for the binding of the free HDMPP specie, although all 
the species experiment interaction with HSA.  
It is expected that the interaction of the ligand HDMPP with HSA occur via 
non-specific binding at the surface of the protein. However, to check if site I and II 
of HSA are possible binding sites for this insulin mimetic complex, competitive 1H 
NMR STD experiments were performed in the presence of warfarin and 
ibuprofen, known binders to site I and II respectively. The displacement of the 
HDMPP ligand by these known inhibitors of HSA after being added to the 
solution of vanadate/DMPP and HSA, reflects the direct interaction of the ligand 
with these sites.  
Analysing 1H STD NMR spectra (Fig. 65) and taking into account the ASTD 
values of Table 11 it is possible to conclude that the most favourable interaction is 
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with the binding site I of HSA. The H6 and H5 aromatic protons were used in 
these calculations because they presented the highest values of saturation 
transfer received from the protein. Although a displacement of the ligand from 
both site I and site II of HSA was observed, according to the ASTD values of the 
solution with HSA and Hdmpp in the absence and presence of warfarin and 
ibuprofen, the binding to site I seems to be favoured relative to site II. 
 
Table 11. Values of ASTD  for H6 and H5 protons for free 0.5 mM VO:HDMPP, 0.4 mM Ibuprofen 
and 0.1 mM Warfarin. The % displacement reflects the decrease of the ASTD value upon the 
addition of known binders. 
 ASTD % of displacement by competition 
HDMPP H6 H5 H6 H5 
Free 6.22 16.42   
Ibuprofen 2.41 2.18 61 86 
Warfarin 0.016 0.038 99 98 
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Figure 65. A)1H NMR spectrum of a solution containing vanadate / DMPP (1:2.5), 0.5 mM in 
vanadate, 0.1 mM Warfarin and 0.030 mM HSA; B) STD spectrum of the same system;  C) 1H 
NMR spectrum of a solution containing vanadate / DMPP (1:2.5), 0.5 mM in vanadate, 0.4 mM 
Ibuprofen and 0.030 mM HSA; D) STD spectrum of the same system. A selective saturation pulse 
(5 s) was applied at the 0 ppm region of the protein. The 30 ms spin-lock pulse was calibrated to 
avoid unwanted protein resonances 
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Figure 66. A) In red  and purple are, respectively, the X-ray structure of warfarin and the 
simulated one; B) Interactions between warfarin and site I of HSA; black dashed lines – hydrogen 
bonds; green solid lines – hydrophobic interactions; green dashed lines – Pi-cation interactions; 
C) overlay of the structures of warfarin (red and Hdmpp (purple) in HSA drug site I, indicating a 
specific competiton for this site; D) Representations of the main residues of the protein interacting 
with the ligand Hdmpp (the residues less than 5 Angstroms from HDMPP (white) and HDMPP 
molecular surface (shaded purple) and hydrogen bonds (light green) ; E) Molecular surface 
(shaded white) and HDMPP (coloured by element – nitrogen as blue, oxygen as red, hydrogen as 
white and carbons as shaded grey)) on drug binding site I; F) Molecular interactions between 
HDMPP and site I of HSA, calculated using Poseview (black dashed lines –hydrogen bonds). 
 
To get an atomic resolution of this interaction virtual screening was 
performed using Autodock Vina 1.1.1. The software was used to assess the three 
dimensional disposition of the binding scenario (Fig. 66).  
Molecular docking software allowed to assess the binding pose and 
probable interactions of the HDMPP ligand within the binding pocket of HSA drug 
site I, the Warfarin binding site. As we can see the Autodock Vina software is fully 
capable of producing good results once the calculated pose for warfarin is almost 
100% overlapped with the pose observed in the X-Ray model of the deposited 
structure. The interactions are depicted in figure 66B. The software does not 
accept vanadium so the docking was done only with the HDMPP alone. This 
might be a good model since the vanadate compound will for sure establish more 
interactions in the binding site, but we can see that it is directly interacting with 
the Warfarin Site (Fig. 66) with the same residues and perfectly lodged in HSA 
binding site I. 
In summary, the interaction is made favourably with the drug binding site I 
and stabilized in a similar manner as its known binding competitor Warfarin. This 
serum protein helps to an effective transport and delivery of the vanadium 
compound. Even though the STD calculation, the free species being the major 
$! %!
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interacting protein, the other species also bind, and the presented model is valid 
to 1:1 and 1:2 species as well. (data not shown - simulations done with 
Phosphorous instead of vanadium, which favours and stabilizes HSA interaction 
with the both solution species, 1:1 and 1:2)  
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8. CONCLUSION AND FUTURE WORK 
! After some considerations made in the Results and Discussion sub-
sections, this final conclusion aims to summary all the data obtained, and also to 
check if all objectives of this work were achieved. 
 Proposals for future work are also stated here as a means to improve the 
outputs of this protocol. 
 
8.1 CONCLUSION 
  
The protocol developed during this work revealed to be very fruitful since 
the enantioselective study is already accepted for publication by Organic and 
Biomolecular Cemistry. 
The protocol can, indeed, accurately calculate dissociation constants, 
describe how the complexes (CA, chiroptical probe, insulin mimetic) interact with 
the protein HSA, and with competitive STD we can tell what is the region of the 
protein involved in this interaction and finally the docking simulations help 
explaning the data obtained by NMR, so the protocol is in full working order. 
STD-NMR can indeed distinguish between the enantiomers SSS-(!)-
[Y.L1]3+ and RRR-(")-[Y.L2]3+ in their binding to HSA and the site is now 
determined to be HSA´s site II, confirming it as stereo-selective. The 3D model 
helped to achieve this first objective. 
The study of binding of CA´s to HSA revealed a stronger interaction of the 
La(DTPA-Cholate) CA analogue and was confirmed by docking simulations. This 
competitive STD technique was able to distinguish were the binding was prone to 
occur in terms of protein region. While La(NAPHTO) appears to have non-
specific binding, the other two CA’s analogues mainly interact with HSA´s binding 
site I.  
The Insulin mimetic VO(DMPP) complex preferably binds to drug-site I of 
HSA and it was obtained that the main interacting specie was the free HDMPP 
but also the other two species are closely interacting with the protein. 
In conclusion, all objectives were achieved on this work, revealing the 
effective usage of STD NMR followed by docking simulations to study the 
interaction of  therapeutic and diagnostic agents with their respective receptors. 
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8.2 FUTURE WORK 
 
The KD values of the contrast agents used can be calculated with 
competition protocols, either by the determination of the IC50 of the binder used 
with know KD (Warfarin, Ibuprofen and N-dansyl sarcosine) on the interaction with 
the Human Serum Albumin used, so with a few effort the constants can be 
obtained within a week of work. Either by direct displacement or by saturating a 
binding site, the protocol can establish if the results agree with the reference 
value or not. This new protocol can also be used in our group in the future.  
 After determining the binding constants and also knowing what ligand 
proton interacts with the protein by the GEM results it is, an even better 
quantitative information about the ligand docking on the protein, could be 
obtained. So some calculations using HADDOCK, which may help improve the 
scoring function and very nice results and projections can be made. 
 Docking simulations using other software could also make possible the 
quantitative and qualitative simulation for vanadium, Yttrium, lanthanum, and 
gadolinium compounds.  
Since the full characterization for these interactions was performed in this work 
my future proposal is to try to implement it in other system rather than HSA, 
perhaps DNA, beta amyloid peptides or even enzymes. 
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10. Appendix 
! It is very useful and user-friendly to consult the main characteristic NMR 
bases on setting up experiments, and achieving not only nice STD spectra but 
also the knowledge to deal with selective saturation, pulse shape and power, how 
to select the desirable frequency and many more other keys to run a NMR 
spectrum. 
 All gCOSY spectra obtained are deposited here as well as the full 
assignments for thos complexed that were not in current literature. 
10.1 gCOSY spectra 
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10.2 NMR REPORT - NMR study of the Thioflavin T and DO3APIB and interaction 
in with beta amyloid peptides 
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STD Spectra for the mixture was acquired with different saturation resonances 
trying to get only protein signal, and TRIM pulse was exhaustively calibrated and 
no real STD effect was observed, for example figure 4.  
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 As shown on the paper when we have the Thioflavin T alone, we see a 
positive NOE on resonances 10 and 6/9 due to the proximity in this dye. When 
we add a protein, in this case, a peptide, we expet that the NOE became 
negative if the compound interacts with the peptide because the compound will 
get the large molecule properties.  
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glycoconjugates with the RCA120 lectin: a saturation
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Abstract The study of ligand–receptor interactions using
high-resolution NMR techniques, namely the saturation
transfer difference (STD), is presented for the recognition
process between La(III) complexes of 1,4,7,10-tetrakis
(carboxymethyl)-1,4,7,10-tetraazacyclododecane monoa-
mide and diethylenetriaminepentaacetic acid bisamide gly-
coconjugates and the galactose-specific lectin Ricinus
communis agglutinin (RCA120). This new class of Gd(III)-
based potential targeted MRI contrast agents (CAs), bearing
oneor two terminal sugar (galactosyl or lactosyl)moieties, has
been designed for in vivo binding to the asialoglycoprotein
receptor, which is specifically expressed at the surface of liver
hepatocytes, with the aim of leading to a new possible
diagnosis of liver diseases. The in vitro affinity constants for
the affinity of the divalent La(III)–glycoconjugate complexes
for RCA120, used as a simple, water-soluble receptor model,
were higher than those of the monovalent analogues.
The combination of the experimental data obtained from the
STD NMR experiments with molecular modelling protocols
(Autodock 4.1) allowed us to predict the mode of binding of
monovalent and divalent forms of these CAs to the galactose
1a binding sites of RCA120. The atomic details of the
molecular interactions allowed us to corroborate and sup-
ported the interaction of both sugar moieties and the linkers
with the surface of the protein and, thus, their contribution to
the observed interaction stabilities.
Keywords Ligand–receptor binding ! Glycoconjugates !
Saturation transfer difference NMR spectroscopy !
MRI contrast agents ! Protein–ligand interaction
Introduction
Molecular recognition events are of paramount importance
in chemistry, biology and biomedicine. A large variety of
techniques allow the elucidation of binding events between
a ligand and its receptor. As key examples, enzyme-linked
immunosorbent assay [1], immunoblotting, radioimmuno-
assay [2], affinity chromatography [3] and surface plasmon
resonance experiments (Biacore) [4] are nowadays com-
monly employed for this task. In recent years, NMR-based
techniques [5] have become increasingly popular when
filling in the existing gap for characterization of molecular
binding processes at high resolution. Transferred nuclear
Overhauser effect spectroscopy [6], nuclear Overhauser
effect pumping [7] and water–ligand observed via gradient
spectroscopy (WaterLOGSY) [8, 9] are particular and
powerful examples of such approaches. Among them, the
saturation transfer difference (STD) NMR technique is
probably one of the most popular and robust methods
[5, 10–14]. This technique allows characterization of
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ligand binding through intermolecular saturation transfer
and, moreover, allows screening of ligand libraries [11], as
well as calculation of affinity constants and mapping the
binding epitope [5, 12–14]. In combination with ligand–
protein docking studies, it may also help to derive a con-
sistent 3D model of the intermolecular complex [15–21].
It is obvious that many diseases share a thin line with
molecular recognition events and that targeting specific
receptors is one of the approaches that may be employed to
prevent, understand and control diseases. The development
of magnetic resonance imaging (MRI) contrast agents
(CAs) specifically targeted to different tissues has become
a priority, and is a most profitable approach in this context.
In particular, and within possible targets, the asialoglyco-
protein receptor (ASGPR) is a lectin-type protein only
found at the surface of hepatocytes and macrophages
[22–25], having a determinant role in the targeting of
exogenous compounds to the liver tissues, either for diag-
nosis or for therapy. On the basis of this knowledge, a new
class of CAs has been developed recently with the intent
for them to be selectively taken up by the hepatic ASGPR
[26–28]. 1,4,7,10-Tetrakis(carboxymethyl)-1,4,7,10-tetra-
azacyclododecane (DOTA)-like chelators were attached to
sugar moieties, galactosyl, glucosyl or lactosyl residues, by
pendant arms containing aliphatic chains and amide bonds,
resulting in monovalent or multivalent glycoconjugate
derivative agents. After the development of the DOTA-
based glycoconjugates [26], diethylenetriaminepentaacetic
acid (DTPA) bisamide based glycoconjugates were also
devised and studied [27]. In both types of CAs, DOTA- and
DPTA-based chelates, the structural characteristics are
similar: a central reporter group complexing a paramag-
netic metal centre (Gd3? for MRI, 153Sm3? for c scintig-
raphy) with high kinetic and thermodynamic stability and
long linear or branched arms with terminal sugar moieties
as targeting groups (Fig. 1).
Carbohydrate–protein interactions are relatively weak
binding processes. Nevertheless, affinity enhancement is
achieved through multiple and simultaneous interactions of
glycosides (multivalency) with their lectin receptors, a
process known as the cluster glycoside effect [29–32]. In
this way, higher valencies of the glycosides produce a
synergistic effect in affinity constants when they bind to
proteins (i.e. tetraglycosides[ triglycosides[ diglyco-
sides[monoglycosides) [33, 34]. However, the way in
which the sugar-based ligands interact with their lectin
receptors in order to increase the binding affinity is still
controversial and, most probably, strongly related with the
particular ligand structure [31]. There are two main
mechanisms by which the cluster glycoside effect may take
place: intramolecular or intermolecular interactions. The
intramolecular binding mode is characterized by the
binding of multiple sugar moieties, within the same gly-
coside molecule, to multiple binding sites at the same lectin
receptor. Therefore, this binding mode is also termed
‘‘chelate-type binding’’, as the glycoside simulates a
Fig. 1 Chemical structures and proton numbering scheme of the 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (DOTA) and
diethylenetriaminepentaacetic acid (DTPA) glycoconjugates
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chelate motif imprisoning the metal atom, in this case the
lectin. Moreover, to make this type of interaction possible,
the binding sites on the protein surface should be close
enough to each other to allow simultaneous spanning of the
interacting sites by the ligand binding moieties. At the same
time, the ligand arms must be significantly long to reach the
different binding sites. A conjugation between the protein
and the ligand morphology must support this type of inter-
action. There are also other properties that favour the intra-
molecular binding mode, such as the presence of a
hydrophobic linker, which may promote this binding mode
by enhancing interactions between the linker and the protein
surface [31, 35, 36]. On the other hand, under the same
conditions, a hydrophilic linker could favour an intermo-
lecular binding mode, which takes place when a single
multivalent glycoside molecule binds to more than one
protein molecule, a process that may finally lead to a
precipitate.
In this context, we present the lectin binding features of
this new class of DOTA- and DTPA-based glycoconjugate
CAs and explore the affinity of the multiderivative glyco-
conjugate agents for a model lectin receptor. To accomplish
this task, four different diamagnetic La(III) chelate ana-
logues (diamagnetic chelates were needed in order not to
quench the STD NMR effect) of the Gd(III) compounds of
this class of CAs were studied, namely the monovalent
La(DOTAGal) and La(DOTALac) and the divalent
La(DOTALac2) and La(DTPAGal2) (Fig. 1). STD NMR
was chosen to study the binding of the DOTA and DTPA
glycoconjugates to a well-known lectin, Ricinus communis
agglutinin (RCA120), that was used as a model of the hepatic
ASGPR. Although the carbohydrate recognition domain of
the H1 subunit of ASGPR [37] would be a better model
system, RCA120 was used as a simple model of the mem-
brane ASGPR in this proof-of-principle study of the method
employed because it has galactose binding affinities in the
same range as ASGPR [38], therefore being largely used for
binding assays of galactose derivatives [39, 40]. RCA120
water solubility also favours the in vitro NMR studies.
RCA120 is a dimeric lectin, consisting of two non-covalently
bound ricin-like monomers. In turn, each ricin-like moiety is
composed of two covalently linked heterochains, chain A
and chain B. Chain A is responsible for the catalytic effect
that gives this protein its toxic character, whereas chain B is
the lectin domain, responsible for sugar affinity. Every
B chain has, in principle, two sugar binding sites, dubbed 1a
and 2c [41–44]. However, the exact number of accessible
binding sites in each B chain of RCA120 was ultimately
confirmed by calorimetric assays to be only one (1a), and its
identity was revealed by site mutations [45–48].
We present a study, at the molecular level, of the mode
of binding of these glycoconjugate derivatives compounds
to RCA120 by using a combination of STD NMR data
and molecular modelling protocols, namely docking
calculations.
Materials and methods
Samples
The DOTA and DTPA glycoconjugate derivatives and their
La(III) complexes were synthesized and characterized as
described previously [26, 27]. The La(III) complexes were
dissolved as 99.9% D2O/10% phosphate-buffered saline
solutions. RCA120 was isolated as previously described
[49]. The protein was dissolved in 99.96% D2O (purchased
from Sigma-Aldrich) in the absence of buffer. The protein
concentration ranged from 10 to 25 lM depending on the
compound studied and the expected affinity for the protein,
in order to achieve a large range of ligand excess. The
concentrations of the ligands were selected to obtain most
of the ASTD points at the beginning of the saturation curve,
with ligand excess raging from 10 to 50, and a point of
large ligand excess, over 200, was also obtained to define
the ‘‘plateau’’ region of the curve. The concentrations of
the protein and ligand were not constant for every com-
pound, and were defined according to the desired ligand
excess ratio and the quantities available.
NMR studies
All 1H NMR spectra were acquired using a 5-mm pulse
field gradient (PFG) triple resonance inverse probe using a
Varian VNMRS 600 MHz NMR spectrometer working at
599.72 MHz. For each sample a 1D 1H spectrum was
obtained, and the spectral assignments from the literature
[12, 26, 27] were used after they had been confirmed by 2D
gradient correlation spectroscopy (gCOSY) spectra (data
not shown). STD NMR spectra were then acquired, where
the double PFG spin echo (DPFGSE) sequence [50] was
used for water suppression. Since in our NMR system the
STD NMR spectra are acquired directly from phase
cycling, the 1D 1H NMR spectra were used as off-reso-
nance references in order to calculate the STD amplifica-
tion factor [12]. All spectra were acquired using the same
parameters: equal spectrometer gain value, spectral win-
dow of 8 kHz, number of scans varied between 128 and
256 for 1D 1H spectra and between 1,024 and 2,048 for the
STD NMR spectra, a previously calibrated spin-lock filter
(T1q) of 30 ms was used to remove protein resonances, the
acquisition time was 1 s and the repetition time was 3.5 s.
STD experiments were performed using a saturation delay
of 2.5 s. To compare the reference spectra with the STD
NMR spectra, the different number of acquisitions was
normalized according to Eq. 1:
J Biol Inorg Chem (2011) 16:725–734 727
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Relative STDð%Þ ¼ ISTD $ 2$ scansreference
I0 $ scansSTD ; ð1Þ
where ISTD is the peak intensity of the STD NMR spectra
and I0 is the intensity of the peaks in the
1H reference
spectra. Then, the peak intensities were normalized to the
STD amplification factor (ASTD) (Eq. 2):
ASTD ¼ relative STD$ ligand excess: ð2Þ
Binding studies
Affinity constant (KD) estimation was performed by
studying the build-up behaviour of the STD NMR spectra
in conditions of constant protein concentration and
increasing ligand concentration. The KD values were esti-
mated by fitting the plotted data points to a one-site binding
model [13, 16] (Eq. 3):
ASTD ¼ aSTD $ L½ &
L½ & þ KD ; ð3Þ
where aSTD is the maximum ASTD and [L] is the total ligand
concentration. Plots and fits were obtained using GnuPlot
version 4.2-3.
Docking calculations
Automated docking was performed using Autodock 4.1 [51]
and the Lamarckian genetic algorithm [52] as a searching
procedure. The Protein Data Bank (PDB) file corresponding
to the protein used, RCA120, was 1RZO. The protein model
was kept rigid, and torsions were allowed only at the ligand
level. Owing to the large number of torsions and the size of
the ligands, only the sugarmoiety and the adjacent armswere
docked. The reporter groups (DOTA and DTPA) were
removed and, in the case of divalent ligands, just one of the
arms was considered. La(III) ligand chelates were designed
in three dimensions using Maestro (Schro¨dinger) [53]. For
glycoconjugate derivatives, grid maps were constructed
using 50 9 50 9 50 points, with a grid box point spacing of
0.303 A˚ and centred some points below the binding site.
The size of the initial random population was set differently
for each compound, 150 for La(DOTAGal) and 50 for
La(DTPAGal2). The other parameters were set common for
all runs, the maximum number of generations was 27,000,
the elitismwas 1, the probability that a gene would undergo a
random change was 0.02 and the crossover probability was
0.80. Fifty docking runs were performed. The maximum
number of generations was reached for these calculations
and the total number of evaluations was kept around
1.1 9 107. For galactose calculations, grid maps were con-
structed using 40 9 40 9 40 points, with a grid box point
spacing of 0.336 A˚ and centred at the ligand that was placed
in the binding site in the PDB file by default. The size of the
initial random population was 50 individuals, the maxi-
mum number of energy evaluations was 1.5 9 107, the
maximum number of generations was 40,000, the elitism
was 1, the probability that a gene would undergo a
random change was 0.02 and the crossover probability
was 0.80. Fifty docking runs were performed. The results
were clustered using a root-mean-square deviation
(RMSD) cutoff of 0.5 A˚.
Results and discussion
Figure 2 represents both the 1D 1H and the STD NMR
spectra of the four La(III)-complexed glycoconjugates in
the presence of RCA120. Resonances from the
1H spectra
were assigned on the basis of data in previous publications
[12, 26, 27] and on gCOSY analysis. The resonances are
identified in Fig. 2, following the proton numbering
schemes shown in Fig. 1. The sugar resonances are the
main visible resonances in the STD NMR spectra, thus
proving that these DOTA/DTPA branched glycoconjugate
derivatives specifically interact with RCA120 through the
sugar moieties. Owing to the nature of the STD experi-
ment, it is possible to characterize the binding epitope of
the ligand for a particular interaction. Table 1 summarizes
the saturation profiles (relative STD) determined for the
sugar and linker protons of the four compounds studied
H protons refer to the protons from the galactosyl residue,
and H0 protons refer to those of the glucosyl residues, in
the case of lactosyl derivatives. The evaluation of the sat-
uration profile of the six (12) groups of protons from the
galactosyl (lactosyl) residues proves that the sugar protons
that remain closer to the protein are always H3 and H2 of
galactosyl residues, with H4 also experiencing great
transfer of saturation [49]. On the other hand, protons H5
and H6/60 seem to remain somehow further from the pro-
tein surface, since weaker STD effects were observed. The
percentage of transferred saturation for protons H5/50,
H66a/606a0 and H3/30 in the case of lactosyl derivatives was
not considered because these peaks are superimposed on
each other. The binding epitope revealed for these glyco-
conjugates is in agreement with the expected epitope on the
basis of previous studies for this type of interaction
[12, 29]. The anomeric protons were not considered in the
group epitope mapping evaluations because the DPFGSE
water suppression scheme dramatically affected its inten-
sity. It is noteworthy that additional STD effects were
observed for the linker protons (see Fig. 2), which will be
discussed later.
After normalization of the acquired data points to the
STD amplification factors (ASTD) [12], the plots of ASTD
versus ligand concentration (lM) were drawn and fit to a
one-site binding model. Figure 3 represents the two plots
728 J Biol Inorg Chem (2011) 16:725–734
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Fig. 2 One-dimensional 1H NMR (top) and saturation transfer
difference (STD) NMR (bottom) spectra of a 0.82 mM La(DOTA-
Gal), b 6.2 mM La(DOTALac), c 1.1 mM La(DOTALac2) and
d 0.58 mM La(DTPAGal2) in the presence of Ricinus communis
agglutinin (RCA120) with the following concentrations: a 25 lM,
b 10 lM, c 15 lM and d 15 lM. Selective saturation (2.5 s) was
performed at the aromatic region of the protein. The spin-lock pulse
was calibrated to avoid unwanted protein resonances
J Biol Inorg Chem (2011) 16:725–734 729
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from the galactosyl and lactosyl derivatives, each one
representing both monovalent and divalent forms. Table 2
summarizes the values of the affinity constants estimated
for the corresponding interactions with the lectin. To esti-
mate the affinity constants for the different compounds, the
data points obtained from the H3 protons of the galactosyl
derivatives were used for the calculations since they
showed the highest degree of saturation, thus allowing a
more accurate KD estimation [16, 17]. Also, because of
degeneration of different proton resonances in the spectra
of the lactosyl derivatives, the affinity constant for these
compounds was estimated according to the data obtained
from the galactosyl H4 proton, which remained fairly
isolated. However, taking into account the recently pub-
lished detailed analysis of the factors affecting the deter-
mination of ligand–receptor dissociation constants by STD
NMR titration experiments [17], one has to consider the KD
values presented here as approximations of the real values.
The calculated KD values (Table 2) reflect an increase in
binding affinity for both divalent compounds relative to the
monovalent ones, also evidenced by the lower ASTD values
output by the fitting curves, with a substantial decrease of
the dissociation rate (koff) with respect to that of the
monovalent analogues, as it is rather unlikely that, when
completely bound, both sugar residues of the divalent
compounds simultaneously dissociate from the two binding
sites [5].
The stronger binding of the divalent compounds to the
lectin clearly observed in the present experiments is in
agreement with findings of previous in vivo studies, where
the higher affinity of the multivalent forms of glycocon-
jugate derivatives of this type showed a more rapid
incorporation by the liver than the monovalent forms [54].
The STD NMR spectra provided additional information
on the slightly different interaction features for the mono-
valent and divalent molecules with RCA120. For the
monovalent compounds, La(DOTAGal) and La(DOT-
ALac) (Fig. 2a, b), the resonances from protons j and k in
the linker arms are barely visible. On the other hand,
several proton resonances are clearly visible in the STD
NMR spectra of the divalent compounds, and it is possible
to measure the saturation profiles of resonances n and o for
La(DOTALac2) and resonances l, gj and hi for
La(DTPAGal2). The calculated STD values for protons n
and o of La(DOTALac2) were 37 and 44%, respectively,
normalized to H2. In the case of La(DTPAGal2) resonance
l was measured to have 29% saturation and resonances gj
and hi had 37 and 28%, respectively, normalized to H3
(Table 1). Although we have to consider that the gj and hi
signal contribution comes from eight protons, we cannot
ignore that the linkers of these divalent compounds interact
with the lectin surface.
A hydrophobic linker is more prone to establish inter-
actions with a lectin protein surface than a hydrophilic one
[55]. In fact, the La(DTPAGal2) linker is longer and more
hydrophobic, when compared with the linker (protons g–j)
of La(DOTALac2). It also displays more torsional degrees
of freedom in solution, thus facilitating the interaction with
the surface of the protein. That might explain why we do
not observe interaction of protons g–j of La(DOTALac2)
with the protein.
The presence of hydrophobic interactions between a
given ligand and the neighbouring regions of the sugar
binding site in the lectin surface has already been reported
[31, 35]. Although very frequently binding features of this
type have been associated with intramolecular, or chelate-
type, binding modes [55, 56], the 3D structure of the
RCA120 protein does not allow such a type of binding. The
X-ray diffraction structure available for RCA120 (PDB file
1RZO) shows a dimer of AB ricin heterodimers in the
crystal. In fact, the distance between the two galactose
binding sites within one heterodimer is 36 A˚, too far for the
Table 1 Summary of the
characterized binding epitopes
with saturation transfer
difference (STD) values relative
to those of H2 or H3 as a
percentage
See Fig. 1 for the structures of
the epitopes
Protons La(DOTAGal) La(DPTAGal)2 La(DOTALac) La(DOTALac2)
H2 94 95 100 100
H3 100 100 – –
H4 93 64 68 94
H5 H6a/6b 64 65 – –
H20 72 80
H40 37 34
k 11
j 10
hi 28
gj 37
l 29
n 37
o 44
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two arms of the divalent ligands to span them and account
for a possible simultaneous intramolecular effect. More-
over, the distance between the two closest galactose
binding sites, each one on each B-chain subunit of the two
dimers, is even larger, more than 50 A˚. Thus, the tenfold
increased affinity of the divalent compounds for the lectin
relative to the monovalent compounds cannot be explained
by an intramolecular mechanism of a cluster glycoside
effect. In the case of an intermolecular mechanism, lectin–
lectin interactions and finally precipitation should occur to
produce the increased affinity, which was not observed in
the present case. Therefore, with the available data, the
statistical effect of the multiple carbohydrate epitopes
present together with the interaction of the linkers with the
protein surface (see later) is considered to be responsible
for the observed increased affinity.
The empirical results of the STD experiments were
substantiated with a 3D model of the complex by using
molecular modelling calculations based on Autodock 4.1
[51]. Docking calculations were then performed for
La(DTPAGal2) with RCA120 binding site 1a, considering
only one of the sugar arms, following the protocol descri-
bed in ‘‘Docking calculations’’. The highest ranking cluster
encompassed eight possible binding conformations, with
the output geometries clustered using a RMSD of 2 A˚.
Three of the eight calculated conformers were selected
according to the orientation of the sugar moiety inside the
binding pocket, and considering they keep conformity with
the STD NMR results and with the chemical nature of the
molecule itself. Indeed, the binding mode obtained was
completely in agreement with that obtained for an isolated
galactosyl moiety, thus validating the orientation of the
saccharide residue of La(DTPAGal2) within the binding
site. Figure 4a shows one representative structure of the
selected cluster, and Fig. 4b represents three superimposed
structures from the above-mentioned calculations. The
galactosyl residues from the different runs, including that
for a single galactose moiety, are oriented in a similar
manner, although they are not perfectly superimposed.
Nonetheless, all the intermolecular hydrogen bonds that
occur for galactose binding also occur for the different
solutions for this glycoconjugate. With respect to the
interactions of the linker with the protein surface, the
models obtained set the long hydrophobic linker of
the La(DTPAGal2) chelate close to a hydrophobic region of
the protein surface, and thus it interacts with the side chains
of different amino acids. Owing to the size of the docked
ligand, the structures obtained can be considered as a good
approximation of the interaction mode, which cannot be
seen within the concept of a rigid, static representation.
Very probably, different orientations of the linker may be
adopted for it to properly interact with the lectin, as sug-
gested by the docking calculations.
Docking studies of the La(DOTAGal) single-arm mol-
ecule with RCA120 binding site 1a were also performed, as
described in ‘‘Docking calculations’’. Only the structures
which fit the STD data were selected for further analysis
(Fig. 5). In this case, the STD data suggested very weak
interactions between the linker of these monovalent
derivatives and the protein surface. Again, the same region
Fig. 3 Direct determination of the KD values of La(III) complexes of
a DOTAGal (circles) and DTPAGal2 (triangles) and b DOTALac
(circles) and DOTALac2 (triangles) binding to RCA120 by fitting the
acquired data points to Eq. 2
Table 2 Individual KD values for the protons of the glycoconjugate
compounds obtained from the STD NMR experiments
Protons Individual KD
value (mM)
Maximum STD
amplification factor
(La)DOTAGal–H3 1.66 6.5
(La)DTPAGal2–H3 0.15 1.6
(La)DOTALac–H4 1.16 5.8
(La)DOTALac2–H4 0.12 2.2
J Biol Inorg Chem (2011) 16:725–734 731
123
of the protein was targeted by the linker, as for
La(DTPAGal2). It can be observed that the charged regions
of the linker were placed near the charged atoms of the
surface amino acids, which could stabilize the conforma-
tion by polar interactions. H–H distances between the
linkers of both docking results for La(DTPAGal2) and
La(DOTAGal) and the surface of RCA120 binding site 1a
Fig. 4 Automated docking structures of one arm of La(DTPAGal2)
in binding site 1a of RCA120. a One of resulting runs is shown in
green and b the three most reliable runs. The single docked galactose
molecule was also superimposed to allow a better comparison, and it
is displayed in orange. Marked in yellow are the hydrogen bonds
considered between the ligand and the protein, involving OH2 and
Lys40, OH3 and Asn46, OH4 and Gly25, and OH6 and Gln35. CH–p
stacking interactions with Trp37 also occur [52]
Fig. 5 Docking results of the sugar-linker moiety of La(DOTAGal).
a One of the docked results and b the superimposed view of all the
selected possible structures. The number of torsional bonds was 13
732 J Biol Inorg Chem (2011) 16:725–734
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were measured using Autodock 4 (Table 3). On average,
protons f–k of the hydrophobic patch of the La(DTPAGal2)
linker are closer to the protein surface protons (calculated
average distance of 2.9 A˚) than protons i–h of the polar
linker of La(DOTAGal) (calculated average distance of
5.8 A˚). In fact, as one moves from the sugar moiety of the
molecule, the polar linker of La(DOTAGal) tends to move
away from the protein surface, whereas the hydrophobic
parts of the La(DTPAGal2) linker far from the sugar
moiety stay quite close to the protein surface.
Finally, Table 4 shows the output values for the calcu-
lated binding structures of La(DOTAGal) and La(DTPA-
Gal2). The intermolecular energy is lower in La(DOTAGal)
and La(DTPAGal2) runs when compared with the single
galactose molecule. As expected from the higher number of
torsions, the average internal energy upon binding is lower in
the La(DTPAGal2) runs than in the La(DOTAGal) runs. The
values should be regarded as merely qualitative, given the
simplification of the model employed.The affinity of gal-
actose for RCA120 is 2.2 9 10
3 M-1 [46], a value which lies
between the calculated values for the monovalent and
divalent compounds, in qualitative agreement with the esti-
mated free energies obtained by docking calculations.
Conclusion
An STD NMR analysis has shown that the divalent
La(DTPAGal2) and La(DOTALac2) glycoconjugate deriv-
atives have higher affinity for the RCA120 lectin than their
monovalent La(DOTAGal) and La(DOTALac) analogues.
This effect is therefore concordant with the results
observed in in vivo binding studies with hepatocyte cells
and the corresponding 153Sm3? chelates [54]. The so-called
cluster glycoside effect may be invoked to explain the
observations. Our studies have tried to clarify the binding
mode of this new class of potential liver imaging agents,
using the RCA120 lectin as a simple model receptor, in
order to provide new insights into the development of lead
compounds and optimization of those already developed.
The STD NMR data, assisted by docking calculations,
suggest the existence of interactions between the linkers of
the divalent compounds and the protein surface.
The structural features of RCA120 and the glycoconju-
gate imaging agents used in this work preclude the
existence of an intramolecular binding process. An inter-
molecular type of binding cannot be considered, as it
would imply protein clustering and precipitation, which did
not occur in the experimental conditions used. Taking into
consideration the STD NMR data and the docking results
obtained, we can conclude that the main interaction
between these ligands and the lectin protein occurs through
the sugar residues, through a combination of hydrogen
bonds, van der Waals forces and CH–p stacking interac-
tions [57, 58], but the hydrophobic linker arms also interact
with the protein surface, especially for the divalent agents.
These interactions, together with a statistical effect of the
presence of multiple carbohydrate epitopes, are considered
to be responsible for the increased affinity of the divalent
compounds for the lectin. We believe that the approach to
study CA–target protein interactions combining NMR and
modelling tools, proposed and exemplified in this work for
Table 3 H–H linker–protein distance of docked arms of
La(DOTAGal) and La(DTPAGal2)
La(DOTAGal) La(DTPAGal2)
Protons Distance (A˚) Protons Distance (A˚)
k 3.2 m 2.8
j 4.1 l 3
i 5.2 hi 2.9
h 6 gj 3.1
Distances were measured relative to Ca G25, Cb E26 and Cb E27 and
are presented as average values
Table 4 Calculated energies
for the ‘‘single arm’’ of
La(DOTAGal) and
La(DTPAGal2) (kcal mol
-1)
The first set of runs 1–4 and
second set of runs 1–3 refer
to La(DOTAGal) and
La(DTPAGal2), respectively
Run La(DOTAGal)/
La(DTPAGal2)
Intermolecular
energy
Internal
energy
Torsional
free
energy
Unbound
system
energy
Estimated
free
energy
Run 1 -8.62 -1.55 ?3.57 -0.46 -6.14
Run 2 -7.01 -2.48 ?3.57 -0.46 -5.47
Run 3 -8.16 -1.45 ?3.57 -0.46 -5.58
Run 4 -8.73 -1.56 ?3.57 -0.46 -6.25
Run 1 -8.60 -1.82 ?4.39 -0.60 -5.43
Run 2 -9.13 -1.62 ?4.39 -0.60 -5.76
Run 3 -7.86 -1.78 ?4.39 -0.60 -4.65
Galactose -6.69 -1.49 1.65 -0.37 -6.16
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the first time, can be very useful in the design of novel
targeted MRI CAs. In particular, novel design and pro-
duction of high-affinity glycoconjugates, such as ones
investigated here, to interact with lectins should focus on
the optimization of the linker arms as a protein binding
complement to the sugar residues, regarding their length,
flexibility and chemical nature. Such an approach will aim
at increasing entropic and enthalpic savings that derive
from the linker. Good knowledge of the structure of the
target receptor is also of extreme importance in order to
design specific and protein-directed ligands.
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Experimental Section 
Materials. Chemicals were purchased from Sigma-Aldrich and used without further purification. 
(SSS)-L and (RRR)-L were synthesised as previously described.1  
Synthesis of (SSS)-[Y.L]Cl3: 1-(6-Methyl-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenyl 
ene)-4,7,10-tris[(S)-1-(1-phenyl)ethylcarbamoylmethyl]-1,4,7,10-tetraazacyclododecane, ligand L 
(26 mg, 0.027 mmol) and yttrium (III) acetate (6.7 mg, 0.025 mmol) were dissolved in methanol:water 
(1:1, 5 mL) and the resulting solution was heated to reflux under argon overnight. The solution was 
then added dropwise to ether (20 mL), the precipitate centrifuged and the solvent decanted. The solid 
was redissolved in acetonitrile and the process repeated to yield a pale yellow solid. This solid was then 
converted to the chloride salt by stirring with Dowex 1!8 200-400 mesh Cl which had previously been 
washed with 1 M hydrochloric acid and neutralised with water. The solid Dowex was removed by 
filtration and the solvent removed by lyophilisation to yield the title compound as a yellow solid (23 
mg, 0.019 mmol, 75%).  
1H NMR (700 MHz, D2O): 0.79 (3H, m, Me.1), 1.11 (3H, m, Me.2), 1.25 (1H, m, cyclen CH2), 1.39 
(1H, m, cyclen CH2), 1.61 (3H, m, Me.3), 1.84 (2H, m, amide CH2), 2.01 (5H, m, 5, 5’, cyclen CH2), 
 2 
2.17 (3H, m, cyclen CH2), 2.26 (1H, m, cyclen CH2), 2.34 (1H, m, amide CH2), 2.52 (2H, m, amide 
CH2), 2.57 (1H, m, 1c), 2.75 (2H, m, cyclen CH2), 2.97 (1H, m, cyclen CH2), 3.20 (3H, m, cyclen 
CH2), 3.46 (4H, m, 4, 4'), 3.33 (1H, m, amide CH2), 3.68 (1H, m, cyclen CH2), 4.17 (1H, m, 2c), 5.14 
(1H, m, 3c), 6.37 (2H, br, amide NH), 6.51 (4H, m, 3e, 3d), 6.76 (1H, m, amide NH), 6.87 (3H, m, 1f, 
2f, 3f), 7.33-7.50 (10H, m, 1e, 1d, 2e, 2d,  aryl CH), 7.75 (1H, m, 2), 8.35 (1H, m, 2'), 9.30 (1H m, 1'), 
9.53 (1H, m, 3), 9.59 (1H, m, 3').  
HRMS (+ m/z): [M]3+ calculated for C57H65N11O3Y, 347.4824; found 347.4816. 
(RRR)-[Y.L]Cl3 was synthesised using an analogous procedure, using (RRR)-L. Spectroscopic 
characterisation was identical to that observed for (SSS)-[Y.L]Cl3. 
 
NMR studies. Solutions for NMR studies were prepared by mixing 99.6% D2O (purchased from 
Sigma-Aldrich) solutions of each complex, HSA (defatted, from Fluka Biochemika, Switzerland) and 
N-dansyl sarcosine, in appropriate concentrations, to a total volume of 200 !L and then transferred to 3 
mm NMR tubes. No buffer was used. 
All 1H NMR spectra were acquired on a Varian VNMRS 600 (14.09 T, 599.72 MHz) NMR 
spectrometer (Coimbra) using a 3 mm pulse field gradient (PFG) inverse probe and on Varian 
VNMRS-700 (16.44 T, 699.731 MHz) NMR spectrometer (Durham). 1H chemical shifts (") are given 
in ppm relative to TSP as internal reference (1H, " 0.0). For each sample, one-dimensional (1D) 1H 
spectra were obtained using a spectral window of 10 kHz, an acquisition time of 2 seconds, a repetition 
time of 5 seconds, 128 scans and a line broadening of 0.6 Hz. The proton 1D spectra were assigned 
using 2D g-COSY spectra. The 1H saturation transfer difference (STD) NMR spectra were acquired on 
the Varian VNMRS 600 (Coimbra) spectrometer using the Double Pulse Field Gradient Spin Echo 
(DPFGSE) sequence2 for water suppression. Since in this NMR system the STD NMR spectra are 
acquired directly from phase cycling, the 1H 1D NMR spectra were used as off-resonance references in 
order to calculate the STD amplification factor.3 All STD spectra were acquired using the same 
parameters: equal spectrometer gain value, the same acquisition parameters as for 1D spectra, except 
that 2048 scans were used. A selective Gaussian saturation pulse of 2.5 seconds was applied at protein 
resonances. A previously calibrated spin-lock filter (T1#) was used to remove protein resonances. All 
spectra were analyzed using Mestre Nova Software v5.3.1-4825. In order to compare the reference 
spectra with the STD NMR spectra, the different number of acquisitions was normalized according to 
equation (1), 
 3 
(1) 
where ISTD is the peak intensity of the STD NMR spectra, I0 is the intensity of the peaks in the 1H 
reference spectra. Then, the peak intensities were normalized to the amplification factor STD (ASTD), 
equation (2), 
(2) 
DFT. The DFT calculations were performed by using the Gaussian 034 package Y3+ complexes; the 
structures of complexes of other lanthanides are likely to be nearly identical. Importantly, however, the 
use of diamagnetic La3+ and Y3+ for DFT calculations avoids a host of largely unresolved theoretical 
issues with spin-orbit coupling and zero-field splitting in open-shell lanthanides. The Y3+ results were 
found to be very similar to those obtained with La3+, and given the similarity of the ionic radii of the 
central lanthanide ions, only Y3+ complex computations were undertaken.  Gaussian 034 logs and 
checkpoints are available upon request. Molecular geometries were optimised in vacuo by using spin-
restricted B3LYP exchange-correlation functional with a compound basis set (ccpVDZ for CHNOFS, 
Stuttgart ECP28MWB for La and WGBS for Y). 
 
Docking. The molecular docking simulations were performed using Autodock Vina 1.1.1. 5 from the 
Scripps Research Institute. Autodock Tools 1.5.4 revision 29 was used to prepare all the pdbqt files for 
Autodock Vina.   
The HSA structure used was the one with the entry 2XVQ.pdb, because this X-ray structure contains 
the Dansyl Sarcosine, which is known to interact with drug site II, and therefore, the adequate model to 
study the possible binding site to our ligands.  
From the structure contained in 2XVQ.pdb, the chain A was selected and polar hydrogen atoms were 
added to the HSA and its nonpolar hydrogen atoms were merged. 
The ligands, obtained from DFT calculations performed previously from Gaussian 03. With Autodock 
Tools automatically add gasteiger charges, merge non-polar hydrogens, detects the aromatic carbons 
and the rotatable bounds.rotatable according to the stereochemistry of the molecule. 
All calculations for protein-fixed ligand-flexible docking were done using the Lamarckian Genetic 
Algorithm (LGA) method. The GRID box parameters used were: center x = 0, center Y = 5, center Z = 
-24, dimension  30 x 30 x30 and spacing of 1 Angstrom, with a total of 29791 total grid points per map. 
STD
referenceSTD
scansI
scansI
=
!
!!
0
2
% STD Rel.
Exc. Lig.    % STD Rel. !=ASTD
 4 
The grid box was set around dansyl sarcosine binding site to fully cover the entire binding site and 
accommodate ligands to move freely. The best pose was chosen with the lowest docked energy, after 
the docking search was completed.  
USFC Chimera (version 1.5.2 build 32411) was used to read the Autodock data and to obtain the 
images /views presented in this work. For the 2D interactions PoseviewWeb 1.97.06,7 was used to 
represent all possible interactions al fully characterize them. It was used 2XVQ.pbd chain A and the 
best poses for all ligands in mol2 files, that retains all the Cartesian coordinates like the pdb files. 
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Supplementary Results 
 
Figure S1. COSY NMR spectrum of (SSS)- ! [Y.L] 3+ (600 MHz, pH 7.0, 295 K) showing partial 
assignments. 
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Figure S2. 1H NMR assignments for the (SSS)- ! [Y.L]3+ complex. 
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Figure S3. 1H STD NMR of 30 µM HSA, 900 µM (SSS)- ! [Y.L]3+ in the absence (upper) and in the 
presence of 2mM N-dansyl sarcosine (! – N-Dansyl Sarcosine resonances) at 25ºC, D2O, 600 MHz, -
0.5 ppm saturation. 
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Figure S4. 1H STD NMR of 30 µM HSA, 900 µM (RRR)- ! [Y.L]3+ in the absence (upper) and in 
the presence of 2mM N-dansyl sarcosine (! – N-dansyl Sarcosine resonances) at 25ºC, D2O, 600 MHz, 
-0.5 ppm saturation. 
 
 
